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Abstract
Ethical clinical trials need both societal and personal equipoise. Recently, personal
equipoise has been disturbed by the introduction of interim analyses; after an interim anal-
ysis has been performed the study administrators have additional information about the
treatments, which is withheld from new recruits. For true informed consent, this infor-
mation should be given to new study recruits to use in making a personal decision about
their desired treatment. We present a method (and the rationale behind the method) that
provides unbiased estimates of hazard ratios when new recruits are given information from
interim analyses and allowed to choose their own treatments. We then developed a novel
procedure that allows for the identiﬁcation of longitudinal gut microbiota patterns (corre-
sponding to the gut ecosystem evolving), which are associated with an outcome of interest,
while appropriately controlling for the false discovery rate. Finally, using novel statistical
models, we investigated the impact of POPs (in particular, non-dioxin-like polychlorinated
biphenyl, IUPAC no.: 153; ”PCB153”) on human health through the disruption of natural
gut microbiota establishment in infants. We created novel distributed lag two-part models
to account for the cumulative exposure of POPs.Contents
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Introduction
This thesis is constructed from three papers; the ﬁrst concerns ethics in clinical trials, and
the later two are focused on gut microbiota. The gut microbiota papers were produced while
working at the Norwegian Institute of Public Health.
In the ﬁrst paper, we discuss that ethical clinical trials need both societal and personal
equipoise. Recently, personal equipoise has been disturbed by the introduction of interim
analyses; after an interim analysis has been performed the study administrators have ad-
ditional information about the treatments, which is withheld from new recruits. For true
informed consent, this information should be given to new study recruits to use in making
a personal decision about their desired treatment. We present a method (and the rationale
behind the method) that provides unbiased estimates of hazard ratios when new recruits are
given information from interim analyses and allowed to choose their own treatments.
We studied the concept of clinical trials in general, and used multiple simulated clinical
trials to demonstrate our method. The main intervention of interest was allowing recruited
subjects to choose their own treatments, after informing them of the interim trial results.
We assessed our methods e↵ectiveness by observing the bias of the estimated hazard ratio
in our simulated clinical trials, and when the true hazard ratio lay between 0.65 and 1, our
method’s bias was within ±0.01. We demonstrate that our method could have saved six
12
women from breast cancer and ten men from HIV infection, in two historical clinical trials.
The main limitation of our method is the risk of bias if confounders are misspeciﬁed in the
model.
True informed consent requires transparency; that is, current information. If the trial
has not been terminated early, then information from the interim analysis must be used
to update the informed consent. This is the ﬁrst paper to propose and validate a random
clinical trial protocol that would allow subjects to choose their own treatments, while still
producing unbiased hazard ratio estimates that can be used in hypothesis tests.
The second paper revolves around obesity and gut microbiota in infants. It is widely
acknowledged that obesity trajectories are set early in life, and that rapid weight gain in
infancy is a risk factor for later development of obesity. Identifying modiﬁable factors as-
sociated with early rapid weight gain is a prerequisite for curtailing the growing worldwide
obesity epidemic. Recently, much attention has been given to ﬁndings indicating that gut
microbiota may play a role in obesity development. This is the ﬁrst longitudinal study
that aims at identifying how the development of early gut microbiota is associated with
expected infant growth. We developed a novel procedure that allows for the identiﬁcation of
longitudinal gut microbiota patterns (corresponding to the gut ecosystem evolving), which
are associated with an outcome of interest, while appropriately controlling for the false dis-
covery rate. Our method identiﬁed developmental pathways of Staphylococcus species and
Escherichia coli that were associated with expected growth. Our method should have wide
future applicability for studying gut microbiota, and is particularly important for transla-
tional considerations, as it is critical to understand the correct timing and design of the
interventions, prior to attempting to manipulate gut microbiota in early life.
The ﬁnal paper is concerned with how PCB153 a↵ects gut microbiota in early infancy.
Gut microbiota has a critical role in human health; understanding its role in early infancy
is of particular interest due to the time dependent windows that rely on microbial stimulus
from the gut. That is, the development of tolerance and the optimal functioning of angiogen-3
esis and stress responses later in life, require time dependent actions in the gut. Persistent
organic pollutants (POPs) are widespread environmental contaminants that are resistant to
environmental degradation through normal processes, which causes them to bioaccumulate
in human and animal tissue and biomagnify in food chains. POPs are known carcinogens
that disrupt natural human systems (endocrine, reproductive, and immune). Using novel
statistical models, we investigated the impact of POPs (in particular, non-dioxin-like poly-
chlorinated biphenyl, IUPAC no.: 153; ”PCB153”) on human health through the disruption
of natural gut microbiota establishment in infants. We created novel distributed lag two-part
models to account for the cumulative exposure of POPs. We then identiﬁed signiﬁcant asso-
ciations concerning POPs a↵ecting gut microbiota species (spp.) groups (from birth through
to day 120 of life). Strong associations were found between POPs and Biﬁdobacterium spp.,
Biﬁdobacterium biﬁdum,a n dLactobacillus spp.. Using these ﬁndings we successfully identi-
ﬁed gut microbiota as a potential vector through which POPs may harm humans; examples
were given for POPs acting as carcinogens and diarrhoeal agents.Chapter 2
Subjects in randomized clinical trials
should be allowed to choose their own
treatments
2.1 Abstract
2.1.1 Background
Ethical clinical trials need both societal and personal equipoise. Recently, personal equipoise
has been disturbed by the introduction of interim analyses; after an interim analysis has been
performed the study administrators have additional information about the treatments, which
is withheld from new recruits. For true informed consent, this information should be given
to new study recruits to use in making a personal decision about their desired treatment. We
present a method (and the rationale behind the method) that provides unbiased estimates
of hazard ratios when new recruits are given information from interim analyses and allowed
to choose their own treatments.
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2.1.2 Methods and ﬁndings
We studied the concept of clinical trials in general, and used multiple simulated clinical
trials to demonstrate our method. The main intervention of interest was allowing recruited
subjects to choose their own treatments, after informing them of the interim trial results.
We assessed our methods e↵ectiveness by observing the bias of the estimated hazard ratio
in our simulated clinical trials, and when the true hazard ratio lay between 0.65 and 1, our
method’s bias was within ±0.01. We demonstrate that our method could have saved six
women from breast cancer and ten men from HIV infection, in two historical clinical trials.
The main limitation of our method is the risk of bias if confounders are misspeciﬁed in the
model.
2.1.3 Conclusion
True informed consent requires transparency; that is, current information. If the trial has not
been terminated early, then information from the interim analysis must be used to update
the informed consent. This is the ﬁrst paper to propose and validate a random clinical trial
protocol that would allow subjects to choose their own treatments, while still producing
unbiased hazard ratio estimates that can be used in hypothesis tests.
2.2 Introduction
The randomized clinical trial has been called one of the “ten deﬁnitive moments” in medical
advances of the twentieth century. It has evolved into “the gold standard by which the
merits of modern drug therapy must be measured.”1 In this evolution care has also been
taken to produce an ethical procedure, but as sometimes happens when building a multi-
story building in stages, one needs to recheck the foundations as the building gets taller,
so too with the randomized clinical trial, we must periodically question our procedures. Of
1J LeFanu: The Rise and Fall of Modern Medicine, New York 2000.6
late we have started requiring interim analyses in clinical trials, and this may have upset
ad e l i c a t eb a l a n c e . T h et i m eh a sc o m ef o ru st oe x p e n ds o m et h o u g h to nh o wt op r o c e e d
ethically.
Clinical trials have an interesting history. Brieﬂy looking back in time we ﬁnd:
For Medicine is not a naked word, a vain boasting, or vain talk, for it leaves
a work behind it: Wherefore I despise reproaches, the boastings, and miserable
vanities of ambition: Go to return with me to the purpose: If ye speak truth, Oh
ye Schooles, that ye can cure any kinde of Fevers without evacuation, but will
not for fear of a worse relapse, come down to the contest ye Humorists: Let us
take out of the Hospitals, out of the Camps, or from elsewhere, 200, or 500 poor
People, that have Fevers, Pleurisies, etc. Let us divide them in halfes, let us
cast lots, that one halfe of them may fall to my share, and the other to yours;
I will cure them without blood-letting and sensible evacuation; but do you do,
as ye know (for neither do I tye you up to the boasting, or of Phlebotomy, or
the abstinence from a solutive Medicine) we shall see how many Funerals both
of us shall have: But let the reward of the contention or wager, be 300 Florens,
deposited on both sides: Here your business is decided.
And so the gauntlet was ﬂung down by the great physician Jean Baptiste van Helmont
(1577-1644) in order to prove his point of view2.P r o g r e s sc a no n l yb em a d eb ye x p l o r i n g
the unknown, by experimentation. With humans we have options, we can reason; we can
extrapolate from the laboratory; the animal model; and even use simulation models on the
computer, but, as has been shown repeatedly, the ﬁnal proof always must come from the
clinical trial.
This point was clear to the townspeople of Milton, Massachusetts who in 1809 vaccinated
2J vanHelmont: Oriatrike, or, Physick reﬁned: the common errors therein refuted, and the whole art
reformed & rectiﬁed: being a new rise and progress of philosophy and medicine for the destruction of diseases
and prolongation of life now faithfully rendered into English by J.C., sometime of M.H. Oxon.7
aq u a r t e ro ft h et o w n ’ si n h a b i t a n t sw i t ht h eK i n eP o x 3.I no r d e rt od o c u m e n tt h ee ↵ e c t i v e n e s s
of the procedure, they invited dignitaries, including the health commissioner from Boston,
to witness a clinical trial. They enlisted twelve children who had been vaccinated (and their
names are given in the report; this was pre-HIPAA). Each of these children was administered
some dry smallpox the town had acquired. They were then placed in an isolated house, and
after ﬁfteen days released to prove to the world that they were free of the smallpox.
Presumably there was no institutional review board in Milton at the time, although why
the parents or guardians of these children would allow such an experiment to take place
is astounding to our current sensibilities. There is no mention of how these children were
chosen. In van Helmont’s case, on the other hand, it is noteworthy to a statistician that to
make the contest fair, and presumably attractive to his adversaries, he proposed casting lots
to see who got to treat which half. Not attractive enough, as there is no record of anyone
taking him up on his challenge, but an accepted way, even at that time, to balance the
unknown. Indeed, this is not the ﬁrst time in history we see lots being used as arbitrage
instruments; after all, the Roman soldiers at the foot of the cross in Calgary, rather than
tear Christ’s garment into equal sized pieces, apparently drew lots to see who would get the
whole vesture.
This quest to make the unpredictable at least seem fair, has been the basis for gam-
bling presumably from time immemorial. The desired end may be achieved by the use of a
randomization device such as an astralagus4,o rad i e ,o rt o d a y ,t h ec o m p u t e r ;a l t h o u g ht o
be precise the computer generated numbers we use in modern random patient assignments
are not random but rather pseudo random numbers, although these retain the important
features of random numbers. It may not be pure coincidence that the ﬁrst book written
on probability was by the famous Milanese physician Girolamo Cardano (Hieronimus Car-
danus, to give him his Latin name)(1501-1576)5,a n di n d e e di tm u s th a v eb e e nh i sp a s s i o n
3Milton.
4F David: Games, Gods, & Gambling: A History of Probability and Statistical Ideas.
5O Ore: Cardano: The Gambling Scholar; With a Translation from the Latin of Cardano’s ‘Book on
Games of Chance,’ by Sydney Henry Gould.8
(and necessity, the Milanese guild would not let him practise medicine in Milan) for gambling
that drove him to the study of probability, but the poor predictability of the outcomes of
medical treatments in his day may also have inﬂuenced his decision to pursue his study of
probability.
It is interesting that a random device was to play a role in the early, proposed clinical
trial of van Helmont. That the practice seemed desirable is also evident in the trials in
the early part of the 20th century where we see that balance in treatment assignment was
maintained by alternating the patients between treatments, the order being determined by
when they arrived on trial. This is just as good a random device as any–arguing that when
a patient shows up is a random event–except that it had a component of predictability, and
thus its intent could be easily subverted; by holding back a patient, for example. Today we
sometimes use what are called blocked randomization schemes6 where, in multi-center trials
especially, a block size is chosen, such as two or four, so that after each block of patients
the treatment allocations are balanced. This is not too far from the alternating scheme
mentioned above, but is a little less predictable.
The desirability of having unpredictable treatment assignment led to the modern ran-
domized trial. The most famous early one being the streptomycin tuberculosis trial in the
UK where, because of the shortage of the availability of the treatment, investigators were
led to draw lots to see who got the streptomycin. As a result they were then spared from
deciding directly who was assigned to which treatment. There was one exception, of course,
when one of the physicians involved was a✏icted by tuberculosis; he was given the drug.
The current rationale for randomization has not changed and still remains one of balance,
especially balance between unknown factors. We follow Laplace’s dictum, “Probability is the
reﬂection of man’s ignorance,” when we appeal to randomization to balance what we cannot.
This is our attempt in clinical trials to achieve the equality available to physical scientists: If
two identical physical quantities are treated di↵erently and subsequently found to di↵er on
6M Zelen: The randomization and stratiﬁcation of patients to clinical trials. In: Journal Chronic Diseases
27 (1974), pp. 365–375.9
some measure, then the di↵erence is attributed to the di↵erent treatments. This is logically
sound because the two started o↵ as being identical. The problem with humans is that,
even if we have an ethical trial design, there are not two identical individuals. So to control
this inherent variability, we create two groups that are as balanced as we can make them, so
that if we treat the two groups di↵erently and do ﬁnd a di↵erence between them, then we
can logically attribute the di↵erence in outcome to the di↵erence in treatment. That is the
theory.
In practice, just as there are no two identical individuals, so too we cannot ﬁnd two groups
perfectly balanced. But if we use a randomization device, then “on average” the two groups
are balanced. Since we follow Laplace’s pronouncement, we force balance according to some
criterion or criteria, such as age, sex, etc., sometimes called confounders, that we know need
to be balanced in order to yield a sensible result when we compare the two groups. Note
that the more of these confounders we force balance on, the more predictable the assignment
becomes, so we tend to balance on few of these and rely on chance to provide the balance, on
average, and then use statistical models to account for the rest. If we ignore an important
confounder, such as sex may be on a particular study, the random assignment may result
in all women on one treatment and all men on another, and no statistical model can rescue
us then, but that is quite unlikely to happen, or at least that is what we believe. The same
logic holds for unknown factors.
This random allocation in a randomized clinical trial is one way of achieving fairness, and
it also allows the statistician to use probabilistic methods to analyze the trial. Underlying the
acceptance of this randomization is the belief that both treatments are equally good. And
this, of course, is the crux of a hotly debated topic. How can two treatments be equally good?
This is where the notion of equipoise, ﬁrst formulated by Freedman7,i su s u a l l yi n t r o d u c e d .
If we phrase it in the case of the generic experimental-versus-standard-treatment framework,
we have that equipoise is the belief, by each investigator who places a patient on the study,
7B Freedman: Equipoise and the ethics of clinical research. In: New England Journal of Medicine 317
(1987), pp. 141–145.10
that the two treatments are equally good. To ease this maybe unrealistic requirement, we
have the interpretation that “the society of knowledgeable practitioners” believes that the
two are equally e↵ective.8
That not everyone believes this equivalence between treatments is clear. For example,
if the trial is being privately funded then some group has decided to spend a lot of time
and money on an experimental treatment that surely they think has a good chance of being
proved better, or at least as good as the standard treatment. But such investors have been
proven wrong so often that reasonable people may discount their predictive capabilities.
But equipoise is a way of achieving a balance between two, at times conﬂicting, wishes:
(a) those of the individual, and presumably his or her physician, who wishes the best available
treatment, and (b) physicians’ and society’s desire to gain knowledge in order to better treat
future patients. This belief, together with an informed consent of the participants, or their
proxies, is the foundation for an ethical trial.
With equipoise reached, one decides the size of the trial to run. Van Helmont felt he
needed “200 or 500 poor people” to make his point, whereas the townspeople of Milton used
only a dozen boys. The size of the trial is important. It is unethical to have too small a trial
just as it is to have too large a trial. When comparing two treatments, say, if the trial is too
small, or underpowered, then chances are that no di↵erence will be found between the two
treatments. That may be the undeclared intent of the trial, but then why subject patients
to any risk? If one treatment is indeed better than the other, we would wish to ﬁnd this
out as soon as possible and place as small a number of patients on the inferior treatment as
possible. In summary, the number of patients one needs on a trial is related to how much
trust we need to place on the results of the trial.
Once the trial is underway, then the delicate balance at the beginning of a trial is in-
creasingly threatened as more knowledge is gained. It is certainly lost if one treatment is
declared better than the other, as most published clinical trials decide. The nub is that
8R Lilford: Equipoise and the ethics of randomization, in: Journal of the Royal Society of Medicine 88
(1995), pp. 552–559.11
to make such a pronouncement for future–untold numbers of–patients may require a higher
level of conﬁdence than if one needs to make the decision just at the personal level.
This point becomes decisive after performing interim analyses in a clinical trial; especially
in sequential trials. The data and safety monitoring committee that oversees clinical trials
is usually charged with making sure that interim analyses are carried out periodically as the
trial proceeds9.A te a c ho ft h em e e t i n g so ft h i sc o m m i t t e ead e c i s i o ni sm a d ew h e t h e rt o
continue or terminate the trial. The latter option is made for various reasons: for example,
safety (the experimental treatment is too toxic); or one treatment has been shown to be
preferred to the other to the desired degree of conﬁdence; or futility (it does not matter how
the rest of the trial goes, the current preference-decision will not be changed).
These are all laudable aims, and this committee is a great improvement in the running of
clinical trials, but what happens at each one of these meetings is that we get progressively
more and more information about the two treatments. At each meeting the information is
usually kept secret if the trial is to continue, but the information should be understandable
to anyone who can interpret statistics-speak. But the problem is that equipoise may now be
disturbed by the new information, even if the decision by the committee is to continue the
trial. This then raises the question of whether it is still ethical to ask more patients to come
onto a trial whilst hiding this newly acquired information from them.
Of course, the crux of the argument is if we think that equipoise has been disturbed.
But how do we determine that? For whom has equipoise been disturbed? This is where
the next patient-to-come-on-trial’s aims and society’s aims possibly become diametrically
opposed. As far as societal beneﬁt being best served, the answer is to continue the trial since
statistical signiﬁcance has not been achieved and thus to the certainty required (however we
measure it) for a societal decision to be made, equipoise has not been disturbed. But when
it comes to the individual patient who may not require as much convincing to believe that
one treatment is better than the other, the answer is not clear; equipoise may thus well be
9J Wittes: Forming your phase iii trial’s data and safety monitoring board: A perspective on safety, in:
Journal of Investigative Medicine 52 (2004), p. 7.12
broached for some individuals, although not for society.
On a personal level, which one of us would not prefer treatment A over treatment B
where the two are comparable inter alia (toxicity, cost, length of treatment etc.) and our
best estimate so far is that A has a 0.6 probability of success and B has a 0.4 probability of
success? It may well be that these estimated probabilities come with standard errors of 0.2
so the di↵erences are not statistically signiﬁcant at a reasonable p-value, and as a result if we
consider making a recommendation for all future patients, we need to get more information.
But the question is when one is making a personal choice for oneself or a loved one, which
would one choose? Society may be correct in not wishing to make any pronouncement about
the two treatments being signiﬁcantly di↵erent, but an intelligent individual may well think
them su ciently di↵erent to make an individual choice. Thus the problem is that personal
equipoise may be lost more readily than societal equipoise.
If as an individual we can make a rational decision to go with treatment A, how can we
as investigators then turn around and ask a patient to submit to a randomization device that
may well decide that that patient gets treatment B? This distinction came to the fore in the
classical case of the acceptance of the use of extracorporeal membrane oxygenation (ECMO)
to treat newborns with persistent pulmonary hypertension in the UK. Possibly inﬂuenced
by the costs of the procedure, the authorities were not convinced by the experience in the
USA and demanded, and mounted, a randomized clinical trial to settle the issue. The
evidence from the USA included trials from Michigan10 where 100 babies were studied, and
ar a n d o m i z e ds t u d y 11 where one control baby died and eleven babies on ECMO survived.
There was a two phased randomized study from Children’s Hospital Boston12 where in the
ﬁrst phase six of ten control babies survived and nine of the nine babies on ECMO survived.
10R Bartlett et al.: Extracorporeal membrane oxygenation (ecmo) in neonatal respiratory failure. 100 cases.
In: Annals Surgery 204 (1986), pp. 236–45.
11R Bartlett et al.: Extracorporeal circulation in neonatal respiratory failure: a prospective randomized
study, in: Pediatrics 76 (1985), pp. 479–87.
12P O’Rourke et al.: Extracorporeal membrane oxygenation and conventional medical therapy in neonates
with persistent pulmonary hypertension of the newborn: a prospective randomized, in: Pediatrics 84 (1985),
pp. 957–63.13
In the second phase twenty babies were treated with ECMO and nineteen survived. These
trials were supported by a register of experience with 715 babies on ECMO between the
years 1980-1987 in 18 neonatal centers in the USA13. To their credit the UK study was
stopped early, but 54 of the 92 babies placed on the control arm died (in contrast to 30 of
the 93 on ECMO). It is di cult to believe that any informed, caring parent of a child born
prematurely and eligible for this study would not choose ECMO for their child.
The argument against revealing the accumulated knowledge of the study as it progresses
is that this action would compromise the study’s scientiﬁc basis. With studies where psycho-
logical considerations, such as the placebo e↵ect, for example, are important and blinding is
used, such a disclosure might well invalidate subsequent data. For example, an early clini-
cal trial, designed by Benjamin Franklin and Antoine Lavoisier to expose Anton Mesmer14,
found it necessary to actually have the patients blindfolded; and thus the origin of the use
of the word blind in the description of studies. They also lied to the patients, tricking them
into believing they were receiving certain treatments that they were not, but that should not
happen today because of informed consent. Informed consent is what makes modern trials
ethical. It is argued in15 that informed consent is certainly necessary, but is not su cient for
an ethical trial, and amongst other conditions necessary to make a trial ethical is respect for
the patient. This respect includes keeping the informed consent document current, which
means including information that may only become available during the performance of the
trial. Surely the patients should be kept informed of information that becomes available
in an interim analysis that may impact on patients’ judgment of equipoise, otherwise the
informed consent form is no longer informed. This may cause problems for those analyzing
the data from such trials, but only if a patient armed with the new information still wishes
13J Toomasian et al.: National experience with extracorporeal membrane oxygenation for newborn respi-
ratory failure. data from 715 cases, in: ASAIO-transactions-American-Society-for-Artiﬁcial-Internal-Organs
34 (1988), pp. 140–7.
14H Herr: Franklin, lavoisier, and mesmer: origin of the controlled clinical trial, in: Urologic Oncology 23
(2005), pp. 346–351.
15E Emanuel/D Wendler/C Grady: What makes clinical research ethical?, in: Journal of the American
Medical Association 283 (2000), pp. 2701–2711.14
to be randomized, is it an informed decision. Furthermore, with our statistical techniques,
we demonstrate that it is possible to obtain unbiased estimates for situations where patients
may choose randomization after a non-signiﬁcant interim analysis has occurred.
2.3 Materials and methods
2.3.1 Scenario
We identiﬁed the following case as a stereotypical problem that highlights the issues at the
heart of the general problem, and then proceeded to propose unbiased estimators that were
valid even in this irregular situation.
Consider the following example to typify the situation: there are two arms in the trial,
one and two, with the intended treatments of A and B, respectively, with 400 people in each
arm. The trial is designed to allow one interim analysis at 50% information (300 deaths) and
one ﬁnal look at 100% information (600 deaths). We model patient accumulation to be such
that every 30 days 100 more people (50 in each arm) are added to the trial until the trial
has 800 patients. Our aim is to estimate the hazard ratio of treatment B versus treatment
A.
At the beginning of the trial we had some form of equipoise, so it was ethical to randomly
assign patients to each treatment. At the interim-look, if the analysis showed that the
di↵erence between the treatments was signiﬁcant then we would terminate the trial, whereas
if the di↵erence was not deemed signiﬁcant, then we wouldl continue with the trial. However,
we may no longer have equipoise as one of the treatments will have been observed as possibly
better, even though the degree to which it is better is not convincing to the societal norms
that deﬁne a “signiﬁcant” di↵erence. If this were the case, then suppose this new information
gained at the interim analysis were to be incorporated into the informed consent form giving
the patients subsequently randomized to the “inferior” (but not signiﬁcantly so) arm the
option to choose the other treatment.15
To be more precise, we deﬁne the triplet A/B/C to denote the hazard where:
• A is either G or W, denoting if the patient is randomised to the better (good) or worse
treatment
• B is either D.Better or D.Current,d e n o t i n gt h ed e s i r et os w i t c ht ot h ea p p a r e n t l y
better treatment if o↵ered, or to stay on whatever treatment they were randomized to
• C is either H.Stay or H.Switch,d e n o t i n gw h e t h e ro rn o tt h ep e r s o nh a ss w i t c h e d
treatments
The main rationale for randomization is to maintain balance between treatment arms; al-
lowing patients to choose other than the randomly assigned treatment may introduce biases,
which may not be measurable. To quantify the situation, before the interim look, we had four
hazards operating in the trial: those who were given treatment A and would remain on it re-
gardless (G/D.Current/H.Stay), those who were given treatment A and would switch given
the new information (not yet available) from the interim analysis (G/D.Better/H.Stay),
those who were given treatment B and would remain on it (W/D.Current/H.Stay), and
those who were given treatment B and would switch (W/D.Better/H.Stay). After the in-
terim look, we had three hazards operating for any new patients in the trial: those who were
given treatment A and would remain on it (G/D.Current/H.Stay), those who were given
treatment B and would remain on it (W/D.Current/H.Stay), and those who would switch
if given the chance (both G/D.Better/H.Stay and W/D.Better/H.Switch,w h i c hw e r et h e
same hazards). We did not think it reasonable to switch from the assigned treatment to an
apparently “lesser” treatment, so we ignored this possibility.
Our problem then involved estimating the true hazard ratio between the two treatments
in the above scenario where, given a non-signiﬁcant interim look and proceeding with the
trial, those on the supposed inferior arm were given the option to switch to the superior arm.16
2.3.2 Basic principles
The idea of asking patients which treatment they would prefer has previously been broached
by Zelen in16. Zelen argues that allowing patients to choose their treatment, and subsequently
performing standard analyses, would possibly result in a lack of statistical e ciency, however,
estimates would ultimately be mostly unbiased if few patients opt to switch treatments. This,
however, does not address the situation where large quantities of patients decide to switch
treatments - a case that our method addressed.
Our method of analysis relied on a Bayesian argument using Monte Carlo methods: we
hypothesised realistic values for the aforementioned four hazards, and simulated a large
number of trials for which we know the true hazard ratios. In doing so, we observed the
distribution of estimated hazard ratios at the ﬁnal look, given the true hazard ratio; that is,
P(estimated ﬁnal HR|true HR).
That is, we took a wide selection of possible values for the hazards G/D.Current/H.Stay,
G/D.Better/H.Stay, W/D.Current/H.Stay,a n dW/D.Better/H.Stay.I nf u t u r ea p p l i c a -
tions, this could be done at the interim look by ﬁnding the mean time to death for each arm
(for similar trials), and inverting it to ﬁnd the rates. Reasonable maximum and minimum
bounds of the hazards could be obtained by four times the maximum estimated rate, and
one-quarter of the minimum estimated rate, respectively. Values could then be selected at
equal spacing between the aforementioned bounds.
For each selection, we simulated the aforementioned study plan: one interim analysis
at 50% information (300 deaths) and one ﬁnal look at 100% information (600 deaths). We
modelled patient accumulation to be such that every 30 days 100 more people (50 in each
arm) were added to the trial until the trial had 800 patients. The option of new patients
choosing their treatment was possible after the interim analysis.
For each selection of hazards, an estimated ﬁnal hazard ratio was produced by analyzing
16M Zelen: A new design for randomized clinical trials, in: The New England Journal of Medicine 300
(1979), pp. 1242–1245.17
the study data after 600 deaths in the normal fashion. This estimate was obviously biased.
We also generated the true unbiased hazard ratio by simulating the same study, but without
any options of treatment choice. We then established a database of relationships (for each set
of hazards H.SET =[ G/D.Current/H.Stay, G/D.Better/H.Stay, W/D.Current/H.Stay,
and W/D.Better/H.Stay]) between the true unbiased hazard ratio and biased estimates that
we obtained through allowing switching to occur. This allowed us to see the probabilistic
relationship between the biased estimates and the true estimates; that is, we created an
estimation of P(estimated ﬁnal HR|true HR). It will aid the reader to imagine the database
as a rectangular matrix with the true hazard ratio values as columns and the estimated ﬁnal
hazard ratio values as entries in the applicable column.
In a simplied case, we had the hazard sets:
H.SETa =[a1,a 2,a 3,a 4]
H.SETb =[b1,b 2,b 3,b 4]
Which produced the true hazard ratios (when no switching is allowed):
HR(H.SETa)
HR(H.SETb)
We then simulated the hazard ratios that occurred when switching was allowed (here for the
sake of simplicity, two simulations per set are displayed, but in practice this number was
10,000):
[HRa(1),HR a(2)] 2 H.SETa
[HRb(1),HR b(2)] 2 H.SETb
We then organized this in the shape of the aforementioned rectangular matrix, as shown in18
Table 2.1.
Table 2.1. Hypothetical database of hazard ratio relationships
HR(H.SETa) HR(H.SETb)
HRa(1) HRb(1)
HRa(2) HRb(2)
Ah y p o t h e t i c a ld a t a b a s eo fh a z a r dr a t i o s ,w h e r et r u es e t so fh a z a r d sa r es t o r e di nt h eﬁ r s t
row, and the observed (biased) hazard ratios are stored in the rows beneath
We estimated P(true HR|estimated ﬁnal HR) by restricting the simulated dataset to
those with estimated ﬁnal hazard ratios within a certain range of interest (i.e. conditioning
on the estimated ﬁnal HR), and formed a probability density function of the counts of the
true hazard ratios corresponding to those observations left remaining17.
2.3.3 Naive approach
Problems did arise, as results were only stored if the interim analysis is non-signiﬁcant, and
non-signiﬁcant results were a lot more likely to occur when the true hazard ratio is closer to
one. Thus if we only calculated the posterior distribution by observing the count of similar
estimates in each true hazard ratio category and then normalizing the distribution to sum to
one, the estimate would be biased towards the null. Because of this, we used the proportion
of observations in each true hazard ratio category as a measure of an estimate’s frequency in
ap a r t i c u l a rt r u eh a z a r dr a t i oc a t e g o r y ,a n dt h e nn o r m a l i z e da l lo ft h ep r o p o r t i o n st os u m
to one.
To restate this problem mathematically, the probability that a trial (with a hazard ratio
HR) would not be terminated early, pHR,( a n dt h u se l i g i b l ef o ri n c l u s i o ni nt h es t o r e dm a t r i x )
was a monotone function that had a positive relationship to the true hazard ratio (only the
17S Jackman: Estimation and inference via bayesian simulation: An introduction to markov chain monte
carlo, in: American Journal of Political Science 44 (2000), pp. 375–404.19
region where the hazard ratio is less than one is considered):
pHR = f(HR);where f(x) <f(y)i fx<y .
Consider the simple case where we only simulate two possible true hazard ratios: 0.8 and
0.4. We know that
p0.6 = f(0.6) <f(0.8) = p0.8
so if we simulate 10,000 trials for each hazard ratio, we can expect 10,000 ⇥ p0.6 =5 0 0a n d
10,000⇥p0.8 =8 ,000 results in the matrix for true hazard ratios of 0.6 and 0.8 respectively.
Thus if we have a true hazard ratio of 0.69 (the exponent geometric mean of 0.6 and 0.8)
for an unbiased estimate we require equal representation in the matrix columns of 0.4 and
0.8. As it is equally likely that the estimate for 0.69 will show up in each column of 0.6 and
0.8, there will be 16 times more observations in the 0.8 column than in the 0.6 column. This
means with regards to estimates:
P(0.8|estimate of 0.69) = 16 ⇥ P(0.6|estimate of 0.69)
and thus
E[True HR|estimate of 0.69] = exp(16 ⇥ log(0.8) + 1 ⇥ log(0.6))/17) = 0.79
It is clear that the estimate is strongly biased towards the less-extreme observation.
If we instead use the prevalence of the observation in each column, then
P(0.8|estimate of 0.69) = P(0.6|estimate of 0.69)20
and thus
E[True HR|estimate of 0.69] = exp(log(0.8) + log(0.6))/2) = 0.69
resulting in an unbiased estimate.
Problems further arose when we noted that we were not performing a simple compari-
son of two hazards, but instead four. When simply comparing two hazards, it is a simple
task to hold one constant (e.g. hazard1 =0 .01) and vary the other (e.g. hazard2 =
0.01,0.012,0.014,...,2), resulting in a uniform spread of hazard ratios to sample from,
while maintaining a fair sampling method with regards to the hazards. When compar-
ing four hazards (G/D.Current/H.Stay, G/D.Better/H.Stay, W/D.Current/H.Stay,a n d
W/D.Better/H.Stay), however, ensuring both a fair sampling method of the hazards and a
uniform spread of resultant hazard ratios to sample from is much harder.
We circumvented this problem by implementing an even uniform spread of the four
hazards over a predetermined range (e.g. G/D.Current/H.Stay, G/D.Better/H.Stay,
W/D.Current/H.Stay,a n dW/D.Better/H.Stay 2 [0.01, 0.012, 0.014, ...,0 . 0 2 ] ) ,c a l c u -
lated the true hazard ratio for each permutation of hazards (HR), assigned these hazard
ratios into a predetermined uniform spread of hazard ratio bins (e.g. [0   0.05],(0.05  
0.1],(0.1   0.15],...,(0.95   1]), and performed all calculations using the spread of bins.
As hazard ratios have all the properties of ratios, it was preferable to create this afore-
mentioned predetermined uniform spread of hazard ratio bins as being uniformly spaced in
the log scale. The sampling was also performed on the log scale so the sampling distribution
was less likely to be skewed, and thus the mean was more appropriate.
The mean was also preferable to the median because the median would only return values
already in the distribution. If the true hazard ratio was not speciﬁed in the hazard ratio
bins, no amount of statistical trickery would result in an unbiased estimate. That is, if we
had two bins that were equally distributed on the log scale: [0.2-0.45] and (0.45-1], with21
corresponding midpoints of 0.30 and 0.67, then to estimate the true hazard ratio we would
sample from each of these bins 10,000 times. If we used the median as the desired estimation
measure, then our unbiased estimate could only be 0.30 or 0.67, whereas if we used the mean,
then any range of estimates were possible.
Performing this naive method resulted in less biased observations than if we analyzed
the data blindly, and the more simulations initially ran and stored in the database of
P(estimated ﬁnal HR|true HR) the better the observations. Taking another logical step,
by adding even more information to the estimation process, it was possible to get even
better estimates.
2.3.4 Additional information and priors
Information was added by conditioning on more information than just the estimated ﬁnal
hazard ratio; we conditioned upon the estimated interim hazard ratio. That, is:
P(true HR|estimated interim HR & estimated ﬁnal HR).
Conditioning on this additional hazard ratio – as opposed to just those previously suggested
– added more information to the sampling process, and allowed us to better estimate the
true hazard ratio18.
When we noticed trends in the bias (e.g. the estimates may have been biased towards the
null in situations where the true hazard ratio was extreme, and biased away from the null
when the true hazard ratio was close to the null) we added a prior to the Bayesian sampling
method19. Priors are generally useful for overarching adjustments to the model, as opposed
to trying to account for additional variation in the model. As our interim look was the least
biased estimate we had (it is not completely unbiased however, as it was biased towards
18Jackman: Estimation and inference via bayesian simulation: An introduction to markov chain monte
carlo (see n. 17).
19Ibid.22
the null because continuing with the trial was conditional upon the interim look being non-
signiﬁcant) we implemented our prior around the interim estimation. In this example, when
the interim estimate was closer to the null, we sampled more from the less-extreme tail, and
when the interim estimate was further away from the null (say a hazard ratio of 0.85 or less)
then we sampled more from the more-extreme tail.
The downside to these additional processes was that we required much more information
in the simulation database, which was costly both in storage and time. The time cost was not
only expensive in terms of simulating the initial database, but also when trying to optimize
the priors (a process that might take many tries) each simulation took much longer as it is
more computationally intensive. We sought to ﬁnd the optimal balance between the amount
of information in the model and the amount of time we had20. Of course, computer time is
trivial when compared to the human cost of clinical trials.
2.3.5 Hypothesis testing
It is also important to realize that the user can still implement hypothesis testing when using
this bias-adjusted technique. By sampling from the posterior distribution, P(true HR|information),
it is possible to get conﬁdence intervals for the true hazard ratio for any level of conﬁdence,
thus allowing hypothesis testing to take place21.I fo n ed e s i r e sp - v a l u e sa so p p o s e dt os e e i n g
if their conﬁdence interval contains the null, then it is possible to derive the p-value by deter-
mining at what quantile the null lies, and then subtracting the value from one, and halving
the resulting value (if a two sided test is desired, otherwise the halving is not required).
20J Stewart: Optimization of parameters for semiempiral methods i. method, in: Journal of Computational
Chemistry 10 (1989), pp. 209–220.
21T DiCicco/B Efron: Bootstrap conﬁdence intervals, in: Statistical Science 11 (1996), pp. 189–228.23
2.4 Results
2.4.1 Naive application
We modelled the previously mentioned scenario, with 50% of the new patients switching
treatments if given the chance. We started by generating our own database: 10,000 trials
for each combination of hazards, with one hazard rate (arm one, those who do not switch)
ﬁxed at 0.01/day, another (arm two, those who do not switch) varied in 0.001 increments
from 0.005 to 0.027, and the ﬁnal two hazard rates (those who switch in both arms) varied
from -0.004, -0.002, 0, 0.002, and 0.004 in an additive manner from the hazard rates of those
who stayed, in their arms of the trial, respectively. The estimation of these 575 hazard ratios
(both the interim and ﬁnal estimates were saved) took approximately a week running on a
3.2 GHz 64 bit core with 6 Gb of RAM.
We then proceeded to (again) simulate a range of hypothetical trials, in order to test our
method’s ability to correctly estimate them. We generated 1,000 trials for each combination
of hazards, with one hazard rate (arm one, those who do not switch) ﬁxed at 0.01/day,
another (arm two, those who do not switch) taking the values 0.01, 0.011, 0.0125, 0.01428,
0.01667, and 0.02 (representing hazard ratios of 1, 0.9, 0.8, 0.7, 0.6, and 0.5 respectively).
The ﬁnal two hazard rates (those who switch in both arms) varied through -0.002, 0, and
-0.002 in an additive manner from the hazard rates of those who stayed in their arms of the
trial, respectively.
One of the issues here was the width of the area around an estimate for it to result in
it being observed within a particular bin, as deﬁned earlier in the paper. After trial and
error, it was decided that the bins should be equally spaced for both the interim and ﬁnal
looks. Common sense would have had us place smaller widths around the interim estimate,
as it had everyone abiding by their correct treatment. However, there were also less people
present, and hence less information than in the ﬁnal estimate, so equal spacing was most
appropriate. Of course, after observing the ﬁt of the model with equal spacing, it is then24
the investigator’s prerogative to alter the width as appropriate.
On applying the naive Bayesian method, modelling
P(true HR|estimated interim HR & estimated ﬁnal HR)
we obtained the results present in Figure 2.1.
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Figure 2.1. Results from the naive Bayesian method
2.4.2 Application with additional information
The main problem with Figure 2.1 is the lack of information; we saw that there was some
crucial element of the data that we were not capturing, as there was an underlying variable
that caused the estimated hazard ratio to bounce up and down in a non-systematic manner.
We concluded that our current model, only conditioning upon the interim and ﬁnal esti-
mates of the hazard ratio, was not capturing the subtleties of how those who would switch25
treatments have di↵erent hazard ratios from those who would stay. We needed to account
for this, yet we had to be mindful of the computational burden of conditioning on extra
variables, so we generated (for each arm of the trial at the interim look) the hazard ratio of
those who would switch, compared to those who would stay.
We addressed this problem of lack of information by generating the aforementioned haz-
ard ratios, and by conditioning on these hazard ratios we modelled
P(true HR|estimated interim HR & estimated ﬁnal HR &
estimated interim HR restricted to only those who would switch &
estimated interim HR restricted to only those who would not switch)
and achieved the ﬁt present in Figure 2.2.
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Figure 2.2. Results from the naive Bayesian method with additional information
It was readily apparent that there was much less randomness to the new model, as26
we accounted for the variability by conditioning upon the hazard ratios between those who
switched and those who stayed, within each arm. That is, by including additional information
into the model, we gained a smoother (and better) ﬁt.
2.4.3 Application with priors
The astute observer can note that there appears to be a trend where the estimates are
biased towards the null when the true hazard ratio is more extreme, and biased away from
the null when the true hazard is less extreme. This is because we discarded results that were
signiﬁcant at the interim look (which is much more likely to occur in the true extreme cases)
and then normalized the results to sum to one. This was ﬁxed by adding a prior to the
Bayesian sampling method22;w h e nt h ei n t e r i me s t i m a t ew a sc l o s e rt ot h en u l l ,w es a m p l e d
more from the less-extreme tail, and when the interim estimate was further away from the
null (a hazard ratio of 0.85 or less) we sampled more from the more-extreme tail.
After applying priors to make the observations less extreme for interim observations less
extreme than 0.84, and more extreme for interim observations between 0.70 and 0.75, and
even more extreme for interim observations below 0.70 results in the ﬁt present in Figure
2.3.
2.4.4 Bias
By applying our method, we obtained functionally unbiased estimates of the true hazard ra-
tio. When the true hazard ratios varied between 1 and 0.55 (most practical clinical scenarios
fall within these bounds), we observed that our bias was within ±0.03, as shown in Figure
2.4.
Within 0.65 to 1, we controlled the majority of the bias to be within ±0.01, and for all
intents and purposes all of the bias was within ±0.02, as shown in Figure 2.5. However, it is
22Jackman: Estimation and inference via bayesian simulation: An introduction to markov chain monte
carlo (see n. 17).27
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Figure 2.3. Results from the Bayesian method with priors applied
worth considering that in a real clinical trial, if the hazard ratio were that extreme, then it
is most likely that the interim analysis would have been signiﬁcant and the trial terminated,
removing the need for our method.
Between 0.55 and 0.5, our estimates started to waiver due to our comparable lack of
information in these areas; given a larger simulation database, these results would be less
biased; similar to those between 1 and 0.55.
2.5 Discussion
By using our method it was shown to be possible to obtain functionally unbiased results,
allowing us to statistically rescue a biased scenario in which a traditional analysis was “sac-
riﬁced” in order to treat patients ethically.
Let us now consider historical clinical trials and start by taking the preventative breast28
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Figure 2.4. Distribution of the bias when the true hazard ratio lies between [0.55,1]
cancer trial for Exemestane23.B yt h ee n do ft h et r i a l ,1 1p a t i e n t so nE x e m e s t a n eh a dd e -
veloped invasive breast cancer, as opposed to 32 on placebo. If the trial conductors had
observed that Exemestane had been slightly more e↵ective at a 50% interim look, which
we can assume happened halfway through trial recruitment, and then half of the remaining
patients to be recruited to placebo had decided to switch to Exemestane, an estimated six
cases (eight less cases in the placebo arm, two more added in the Exemestane arm) of breast
cancer could have been averted. That is, the total number of cases of breast cancer in this
trial could have been reduced from 43 to 37; a reduction of 14% of women in this trial from
developing breast cancer, with no additional cost or logistical e↵ort to the study.
Similarly, in this trial for preexposure chemoprophylaxis for HIV prevention24 by the end
23P Goss et al.: Exemestane for breast-cancer prevention in postmenopausal women, in: The New England
Journal of Medicine 364 (2011), pp. 2381–2391.
24R Grand et al.: Preexposure chemoprophylaxis for hiv prevention in men who have sex with men, in:
The New England Journal of Medicine 364 (2010), pp. 2587–2599.29
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Figure 2.5. Distribution of the bias when the true hazard ratio lies between [0.65,1]
of the trial 36 patients on antiretroviral chemoprophylaxis became infected with HIV, and 64
on placebo were likewise infected. With the same assumptions as in the Exemestane trial,
ten people (sixteen less cases from the placebo arm, six more added to the antiretroviral
arm) could have avoided being infected with HIV. Again, decreasing the number of infected
from 100 to 90, a reduction of 10% of men in this trial from being infected with HIV, with
no additional cost or logistical e↵ort to the study.
True informed consent requires transparency; that is, current information. If the trial
has not been terminated early, then information from the interim analysis must be used to
update the informed consent. It is possible to achieve this by implementing our method,
and doing so has the potential to stop many needless adverse events in the modern clinical
trial setting. By altering the statistical analysis process it was possible to save six women
from breast cancer, and ten men from HIV infection, in just two clinical trials. These
numbers become even more important when multiplied across the vast number of clinical30
trials performed each year.
To the best of our knowledge, this is the ﬁrst paper to propose and validate a random
clinical trial protocol that would allow subjects to choose their own treatments, while still
producing unbiased hazard ratio estimates that can be used in hypothesis tests.Chapter 3
Novel developmental analyses identify
longitudinal patterns of early gut
microbiota that a↵ect infant growth
3.1 Abstract
It is widely acknowledged that obesity trajectories are set early in life, and that rapid weight
gain in infancy is a risk factor for later development of obesity. Identifying modiﬁable factors
associated with early rapid weight gain is a prerequisite for curtailing the growing world-
wide obesity epidemic. Recently, much attention has been given to ﬁndings indicating that
gut microbiota may play a role in obesity development. This is the ﬁrst longitudinal study
that aims at identifying how the development of early gut microbiota is associated with
expected infant growth. We developed a novel procedure that allows for the identiﬁcation of
longitudinal gut microbiota patterns (corresponding to the gut ecosystem evolving), which
are associated with an outcome of interest, while appropriately controlling for the false dis-
covery rate. Our method identiﬁed developmental pathways of Staphylococcus species and
Escherichia coli that were associated with expected growth. Our method should have wide
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future applicability for studying gut microbiota, and is particularly important for transla-
tional considerations, as it is critical to understand the correct timing and design of the
interventions, prior to attempting to manipulate gut microbiota in early life.
3.2 Introduction
Gut microbiota has a critical role in human health1;e a r l yi n f a n c yi so fs p e c i a li n t e r e s tb e c a u s e
the early life period is a determinant for the subsequent adult-like microbiota. Once the ﬁrst
microbes arrive in the sterile gut of the newborn, a dynamic process starts, where activation
of genes and expression of receptors in the host plays an important role for the building of
niches and the further selection of microbes. More importantly, studies on germ free animals
have revealed the presence of time-dependent exposure windows that rely on microbial stimuli
from the gut2 (i.e. development of tolerance3,s e n s i t i v i t yt ob i o g e n i ca m i n e s 4,i n ﬂ u e n c e so n
cecum size5,a n do p t i m a lf u n c t i o n i n go fd i v e r s es y s t e m s ,s u c ha sa n g i o g e n e s i s 6 and stress
responses7).
Obesity has been linked to gut microbiota in humans, by being associated with reduced
1F Backhed et al.: Host-bacterial mutualism in the human intestine, in: Science 307 (2005), pp. 1915–20; T
Mitsuoka: Intestinal ﬂora and aging, in: Nutrition Reviews 50 (1992), pp. 438–46; J Roung/S Mazmanian:
The gut microbiota shapes intestinal immune responses during health and disease. In: Nature Reviews
Immunology 9 (2009), pp. 313–23; PJ Turnbaugh et al.: A core gut microbiome in obese and lean twins, in:
Nature 457 (2009), pp. 480–4; B Bjorksten et al.: The intestinal microﬂora in allergic estonian and swedish
2-year-old children, in: Clinical and Experimental Allergy 29 (1999), pp. 342–6; S Mazmaniam/J Round/
D Kasper: A microbial symbiosis factor prevents intestinal inﬂammatory disease. In: Nature 453 (2008),
pp. 620–5.
2C Thompson/B Wang/A Holdes: The immediate environment during postnatal development has long-
term impact on gut community structure in pigs, in: ISME 2 (2008), pp. 739–48.
3N Sudo et al.: The requirement of intestinal bacterial ﬂora for the development of an ige production
system fully susceptible to oral tolerance induction, in: The Journal of Immunology 159 (1997), pp. 1739–45;
S Mazmanian et al.: An immunomodulatory molecule of symbiotic bacteria directs maturation of the host
immune system, in: Cell 122 (2005), pp. 107–18.
4B Gustafsson/T Midtvedt/K Strandberg: E↵ect of microbial contamination on the cecum enlargement
of germ free rats, in: Scandinavian Journal of Gastroenterology 5 (1970), pp. 309–314.
5Ibid.
6T Stappenbeck/L Hooper/J Gordon: Developmental regulation of intestinal angiogenesis by indigenous
microbes via paneth cells, in: Proceedings of the National Academy of Sciences of the United States of
America 99 (2002), pp. 15451–5.
7N Sudo et al.: Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for
stress response in mice, in: The Journal of Physiology 558 (2004), pp. 263–75.33
bacterial diversity and altered representation of bacterial genes and metabolic pathways8.
Since rapid weight gain in early life is a risk factor for the later development of obesity9,w e
aimed to study whether early infant gut microbiota was associated with expected growth in
the ﬁrst six months of life. As gut microbiota can be altered, or even transplanted10,t h e r e
is large potential for future medical interventions.
We describe a novel method that identiﬁes patterns of gut microbiota exposures associ-
ated with potential time-dependent exposure windows in longitudinal data. We implement
this method in the Norwegian Microﬂora Study (NOMIC) to reveal which patterns of gut
microbiota (representing the gut ecosystem evolving) are associated with expected infant
growth.
This is the ﬁrst longitudinal study that aims at identifying how the development of early
gut microbiota a↵ects infant growth. Proper knowledge of the time dependencies of gut
microbiota as an exposure is a crucial underpinning before experimental attempts to manip-
ulate early gut microbiota can be made. In light of this, our method will have considerable
future applications, especially in the translational area of gut microbiota research.
3.3 Materials and methods
3.3.1 Study population
NOMIC is a birth cohort designed to study the establishment of gut microbiota during
infancy and its consequences for child health. Participating mothers were recruited to the
NOMIC study by a paediatrician at the maternity ward in a county hospital in South Norway.
The recruitment protocol purposefully oversampled preterm children; whenever a preterm-
birth mother was enrolled, two mothers of consecutively born term infants were recruited.
8Turnbaugh et al.: A core gut microbiome in obese and lean twins (see n. 1).
9P Monteiro et al.: Birth size, early childhood growth and adolescent obesity in a brazilian birth cohort,
in: International Journal of Obesity 27 (2003), pp. 1274–82.
10Turnbaugh et al.: A core gut microbiome in obese and lean twins (see n. 1).34
The recruitment started in November 2002 and was completed in May 2005. Eligibility
criteria required that mothers were ﬂuent in Norwegian and a resident in the pertinent
geographic area. The study was approved by the Norwegian Data Inspectorate and the
Regional Ethics Committee for Medical Research.
After the informed consent forms were signed by the mothers, containers for fecal samples
and a questionnaire were provided to the participants at the maternity ward. The mothers
were asked to collect and freeze one fecal sample from themselves at postpartum day 4,
as well as samples from their infants when they were 4, 10, 30, and 120 days old. Study
personnel retrieved the fecal samples and kept them frozen during transport to the Biobank
of the Norwegian Institute of Public Health, Oslo, where they were stored at -20 C upon
arrival. Further questionnaires were sent to the families when their infants were aged 6, 12,
18, and 24 months.
Six hundred and one mothers agreed to participate in the NOMIC study, however, 86
(14%) of these mothers never returned any fecal samples, which left 524 infants with available
fecal samples from one or more occasions. Children that were preterm (152), born via
caesarean section (169), or had been exposed to antibiotics before day 4 of life (124), were
then excluded from the current analysis, leaving 246 children.
3.3.2 Outcome
Mothers extracted information on weight from their “baby health visit” cards and reported
this information in questionnaires. Information on gestational age and preterm delivery was
obtained from the Medical Birth Registry of Norway.
To be included in the analysis, we required birthweight and another weight measurement
within 122 to 244 days of birth (approximately 4 to 8 months). These two measurements
are henceforth referred to as measurements at birth and six months of life. If multiple
measurements were available during the latter period, the closest to 6 months was used.
Data from 218 children (110 females and 108 males) met the inclusion criteria.35
The infants’ weights were expressed as an age and sex standardised Z-score. Following
recommendations from the Norwegian Health Directorate11, we used the World Health Or-
ganisation’s weight-for-age growth curves12 to generate these Z-scores. The Z-score of the
weight at birth (Z0i)w a sc o m p a r e dt ot h eZ - s c o r eo ft h ec h i l da ts i xm o n t h so fl i f e( Z6i).
We deﬁned the outcome of interest to be the di↵erence in Z-scores: Yi = Z6i   Z0i.T h i s
deﬁnition was chosen to be in concordance with the current literature, where the most fre-
quent deﬁnition of rapid growth was a Z-score change in weight-for-age13.I fac h i l d ’ sZ - s c o r e
deviated between time periods, it was indicative of deviant growth and labelled as either
increased growth (reaching higher weights than expected from its birthweight) or decreased
growth (undershooting the target weight and reaching lower weights than expected).
The distribution of the di↵erence in Z-scores was found to be approximately Normally
distributed, with a mean of  0.29, median of  0.38, and IQR of  0.80 to 0.24 for females,
and a mean of  0.13, median of  0.18, and IQR of  0.82 to 0.57 for males. To aid in
the interpretation of Z-scores, the relationship (at di↵erent birth weights) between change
in Z-score and weight at six months is displayed in Figure 3.1. Table 3.1 contains further
descriptive characteristics of the study participants.
3.3.3 Exposures
16S rRNA gene clone libraries were constructed from DNA extracted from the fecal samples
obtained on days 4, 10, 30, and 120. Detailed information about this process can be found
in a previous paper from the NOMIC study14.
The exposures of interest are intensity readings for 22 probes, encoding di↵erent gut
11Arbeidsgruppe: Nasjonale faglige retningslinjer for veiing og maaling i helsestasjons - og skolehelsetjen-
esten, Oslo, Norway 2010.
12World Health Organization: WHO Child Growth Standards: Length/height-for-age, weight-for-age,
weight-for-length, weight-for-height and body mass index-for-age: Methods and development, Geneva,
Switzerland 2006.
13P Monteiro/C Victoria: Rapid growth in infancy and childhood and obesity in later life - a systematic
review, in: Obesity 6 (2005), pp. 143–154.
14M Eggesbo et al.: Development of gut microbiota in infants not exposed to medical interventions, in:
Acta Pathologica, Microbiologica et Immunologica Scandinavica 119 (2011), pp. 17–35.36
Figure 3.1. Relationship between weight at six months and change in Z-score. The
relationship is displayed for multiple birthweight percentiles. A change in Z-score of 0
corresponds to theoretically perfect growth at six months. If a male child was born at the
75th percentile, then their expected weight at six months would be 8.5 kg (y-axis),
corresponding to 0 change in Z-score (x-axis) on the right panel. If the child instead
weighed 9.0 kg at six months (y-axis), then that would correspond to a +0.5c h a n g ei n
Z-score (x-axis).
microbiota species (spp.) groups at 4, 10, 30, and 120 days since birth. The probes, labelling
sequence, and target bacteria spp. groups are displayed in Table 4.2. The frequency of each
probes detection, stratiﬁed by day and sex, are shown in the appendix (Figure A.1).
Each intensity reading at every time point is dichotomised into either detected or non-
detected. We selected this categorisation since we had no information on the distributions of
the di↵erent probes’ intensities in the average population, i.e. it was not possible to choose
appropriate demarcations for low, moderate, or high levels.
Each microbiota spp. group were examined individually.
3.3.4 Confounders and e↵ect modiﬁcation
Information on potential confounders was obtained by questionnaires ﬁlled in by the mothers
and from the Medical Birth Registry of Norway. Variables considered a priori to be potential37
Table 3.1. Descriptive characteristics of study participants
Characteristic Description
Maternal smokers (%) 11.5
Twins (%) 3.3
Siblings (%) 61.8
Birthweight (Kg) 3.58 (3.27, 3.88)
Gestational age (days) 284 (277, 288)
Maternal age (yrs) 30 (28, 33)
Maternal BMI 24 (21, 26)
Sample size 218
Statistics are displayed as median (IQR) or only %. Sex speciﬁc results were not noticeably
di↵erent from the above results.
confounders were antibiotics use (after day 4 of life), sex, milk substitutes, maternal smoking,
and parity, however, stepwise regression procedures led to the removal of all considered
confounders due to a lack of e↵ect.
When considering the relationship between microbes and growth, our initial investigations
found evidence for e↵ect modiﬁcation by sex. This led us to perform separate stratiﬁed
analyses.
3.3.5 Time-speciﬁc analyses
We were interested in identifying time points at which the detection of speciﬁc gut microbiota
spp. groups were signiﬁcantly associated with growth trajectory. That is, we investigated
whether we could identify any time points, where the detection of gut microbiota spp. groups,
shifted the growth outcome, the mean change in Z-score. We modelled this relationship by
including the detection of gut microbiota at each time point (days 4, 10, 30, and 120)
separately, using a standard linear regression model (separately for every gut microbiota
spp. group):
Yi = 0,jk +  1k · Xi,4k +  2k · Xi,10k +  3k · Xi,30k+
 4k · Xi,120k + ✏i,jk,38
Table 3.2. Probes and their targets
#P r o b e m a t c h L a b e l l i n g
1 Enterococcus spp. TCATCCCTTGACGGTATCTAA
2 Lactobacillus spp. GTCAAATAAAGGCCAGTTACTA
3 Lactobacillusi CAGTTACTCTGCCGACCATT
paracasei/case
4 Staphylococcus spp. ACACATATGTTCTTCCCTAATAA
5 Streptococcus spp. AGTGTGAGAGTGGAAAGTTCA
(↵-hemolytic)
6 Clostridium spp. TCAACTTGGGTGCTGCATTC
7 Lachnospiraceae spp. AGCTAGAGTGTCGGAGAGG
8 Veillonella spp. GATTGGCAGTTTCCATCCCAT
9 Lachnospiraceae spp. TATCAGCAGGAAGATAGTGA
10 Lachnospiraceae spp. AGTCAGGTACCGTCATTTTCT
11 Lachnospiraceae spp. ACTGCTTTGGAAACTGCAGAT
12 Pseudomonas spp. GTAGAGGGTGGTGGAATTTC
13 Escherichia coli GAGCAAAGGTATTAACTTTACTC
14 Enterobacteriaceae CGAAACTGGCAGGCTAGAGT
other than E. coli
15 Gammaproteobacteria CCTGGACAAAGACTGACGCT
16 Varibaculum spp. TTGAGTGTAGGGGTTGATTAG
17 Biﬁdobacterium longum GAGCAAGCGTGAGTAAGTTTA
including subsp. infantis
18 Biﬁdobacterium biﬁdum CCGAAGGCTTGCTCCCAAA
19 Biﬁdobacterium breve CACTCAACACAAAGTGCCTTG
20 Biﬁdobacterium spp. GCTTATTCGAAAGGTACACTC
ACCCCGAAGGG
21 Bacteroides fragilis GGGCGCTAGCCTAACCAG
22 Bacteroides spp. ATGCATACCCGTTTGCATGTA
Targets of the probes, taken from previous paper15.39
where Yi is the change in Z-score for the ith infant (i =1 ,...,n), and Xi,qk denotes the
detection of the kth gut microbiota spp. group (k =1 ,...,22) at the qth time point (q =
4,10,30, and 120).
We then tested  ik for signiﬁcance, controlling the false discovery rate at 20% (and again
at a more stringent 5%) by using a mixed directional false discovery rate method16.B r i e ﬂ y
summarising the method, we deﬁned Pik as the p-value for the test:
H
i
0k :  ik =0 ( 3 . 1 )
H
i
1k :  ik 6=0
for i =1 ,...,4a n dk =1 ,...,22. We then treated H0j as the intersection of all Hi
0k over i,
and H1k as the union of all Hi
1k over i.T h ef o l l o w i n gp r o c e d u r ew a st h e nu n d e r t a k e n :
1. The Benjamini-Hochberg method was applied at level ↵ to test H0k against H1k simul-
taneously for k =1 ,...,22, based on the Bonferroni pooled p-values Pk =m i n k(Pik)⇥4
2. Rd e n o t e st h et o t a ln u m b e ro fn u l lh y p o t h e s e sr e j e c t e d .
3. All  ik were tested, and Hi
0k was rejected with adjusted signiﬁcance level ↵⇤ = ↵ ⇥
R/(num tests) = 0.05 ⇥ R/(22 ⇥ 4)
3.3.6 Exposure patterns for an evolving gut ecosystem
It is conceivable that, in an infant, it is not the e↵ect of the gut microbiota at a singular
time point, but rather the gut ecosystem evolving over time, which inﬂuences growth. To
capture this evolution, it is possible to describe an infant’s exposure to gut microbiota as a
pattern over time. For example, one infant’s pattern could be a gut microbiota spp. that is
detected at days 4, 10, and 30, then non-detected at day 120. Each combination of possible
16W Guo/S Sarkar/S Peddada: Controlling false discoveries in multidimensional directional decisions, with
applications to gene expression data on ordered categories, in: Biometrics 66 (2010), pp. 485–492.40
Figure 3.2. All possible exposure patterns in the data. “+” and “ ”r e p r e s e n td e t e c t i o n
and non-detection respectively. For example, pattern 8 indicates detection at day 4,
followed by non-detection at days 10, 30, and 120.
values of the gut microbiota (detected or not detected) at di↵erent time points (4, 10, 30,
120 days) was considered to be a pattern.
If a pattern was observed to occur less than 15% of the time, it was not included as a
testable pattern. All 16 possible patterns are displayed in Figure 3.2. Let µjk,4 denote the
population mean for the growth outcome variable (change in Z-scores, representing di↵erence
from expected growth) of infants with (four time point) pattern j, j =1 ,2,..,16 for the kth
gut microbiota spp., k =1 ,2,...,22. Let ˆ µjk,4 denote the estimate of µjk,4 using the sample
mean and let se(ˆ µjk,4)d e n o t et h es t a n d a r de r r o ra s s o c i a t e dw i t ht h es a m p l em e a n .
Using ˆ µjk,4 and se(ˆ µjk,4)f o re a c hp a t t e r na n dg u tm i c r o b i o t as p p . g r o u p ,w ea p p l i e d41
Tuke’s method17 to test for equivalence to zero:
H0 : |µjk,4| ✏, ✏ > 0( 3 . 2 )
H1 : |µjk,4| <✏
where ✏ was chosen to be 0.67. This boundary was chosen because paediatricians are con-
cerned when a child crosses two or more major centiles (2nd, 5th, 10th, 25th, 50th, 75th,
90th, 95th, and 98th) on the growth chart. For a child born on the 50th percentile (3.346
Kg boy/3.232 Kg girl) this corresponds to a change in Z-score of ±0.67. This is a common
boundary choice for studies focusing on rapid growth in infants18.T h em e a no fo u rg r o w t h
variable was chosen, instead of an analysis of contrasts using a linear regression model, be-
cause we were unable to select an appropriate reference pattern (from those displayed in
Figure 3.2). In this analysis, we were concerned with identifying which gut microbiota spp.
group patterns corresponded to a mean change in Z-score that was signiﬁcantly close to zero
(i.e. did not deviate from expected growth). This is in contrast to the previous time-speciﬁc
analysis, which was focused on the relative shift in change in Z-score, when the exposure
was either present of absent.
Similar to the previous analysis, we controlled the false discovery rate at 5% by using the
mixed directional false discovery rate method19.O n c ew ei d e n t i ﬁ e das i g n i ﬁ c a n tp a t t e r n( i . e .
one where µjk,4 is close to 0), we tested to see if some time points might be superﬂuous and
not adding information; for example, it may be that only the ﬁrst 30 days of exposure that
a↵ect growth, so the last time point (day 120) would not be relevant and could be removed
from the pattern. From the mixed directional false discovery rate method20,e a c hf o u rt i m e
17J Tuke/G Glonek/P Solomon: P-values, q-values and posterior probabilities for equivalence in genomics
studies, in: arVix 2012.
18Monteiro/Victoria: Rapid growth in infancy and childhood and obesity in later life - a systematic review
(see n. 13).
19Guo/Sarkar/Peddada: Controlling false discoveries in multidimensional directional decisions, with appli-
cations to gene expression data on ordered categories (see n. 16).
20Ibid.42
point pattern was tested at an adjusted signiﬁcance level of ↵⇤;i ft h ep - v a l u eo fp a t t e r njk,4
(Pjk,4) was less than ↵⇤/2t h e n( b yu s i n gaB o n f e r r o n ia d j u s t m e n t )w eh a dt h eo p p o r t u n i t y
to perform an additional test to pattern jk,4 without risk of losing the signiﬁcant result for
the four time point pattern.
That is, consider the p-values of the patterns jk,4, jk,4 without day 120 (jk,3), jk,4 without
days 30 and 120 (jk,2), and jk,4 without days 10, 30, and 120 (jk,1), to be denoted as Pjk,4,
Pjk,3, Pjk,2,a n dPjk,1,r e s p e c t i v e l y .T h ef o l l o w i n gp r o c e d u r e sw e r ep e r f o r m e da f t e rﬁ n d i n ga
four time point pattern jk,4 whose mean is signiﬁcantly close to zero:
1. If Pjk,4 <↵ ⇤/2, then jk,3 was tested at signiﬁcance level ↵⇤/2
2. If Pjk,3 <↵ ⇤/3, then jk,2 was tested at signiﬁcance level ↵⇤/3
3. If Pjk,2 <↵ ⇤/4, then jk,1 was tested at signiﬁcance level ↵⇤/4
The process ended when a pattern’s mean was either not signiﬁcantly close to zero, or
when Pjk,q (q =1 ,...,4) was not large enough to allow continued testing. This process
controlled the false discovery rate, while simultaneously ensuring that no signiﬁcant ﬁnding
was subsequently lost by the additional testing to remove superﬂuous time points. A short
proof, that this adaptation still retains control of the false discovery rate, is provided in the
appendix. By implementing this adaptation, the resultant test was:
H0 :m i n
 
|µjk,4|,|µjk,3|,|µjk,2|,|µjk,1|
 
  0.67
H1 :m i n
 
|µjk,4|,|µjk,3|,|µjk,2|,|µjk,1|
 
< 0.67
The data reduction process was only considered from the right side of the pattern to avoid
confounding. By deﬁnition, a confounder must a↵ect both the exposure and outcome, and
it is not possible for an exposure at day 120 to a↵ect the exposure between days 4 and 30.
In contrast, an exposure at day 4 may inﬂuence the exposure at day 10, and is therefore a
possible confounder. We stress that, by only undertaking this process on the right side of43
the pattern, we do not imply that the right side of the pattern is less important. Instead,
we view the process as adding information where possible (by culling superﬂuous points on
the right side of the pattern) and leaving the pattern otherwise alone.
3.3.7 Post-hoc screening of results
If a pattern was found to have its mean signiﬁcantly close to zero (i.e. the null hypothesis
in (3.2) is rejected), the mean of the pattern’s crude contrast (i.e. if detection at days 4
and 10 was signiﬁcant, the crude contrast would be non-detection at days 4 and 10) was
tested for di↵erence to zero, using a t-test at ↵ =5 % .I ft h ec r u d ec o n t r a s tw a sn o tf o u n dt o
be signiﬁcantly di↵erent from zero, the pattern was discarded from the signiﬁcant ﬁndings.
In the event of a signiﬁcant crude contrast, a Welch two sample t-test was performed to
test if the means of the pattern and crude contrast di↵ered from each other. This test was
performed at a signiﬁcance level of ↵ =1 0 %d u et ot h ed e c r e a s ei ns a m p l es i z e( a n dh e n c e
power) when only considering the set of infants with either the pattern of interest or the
crude contrast. Tests found to be signiﬁcant at ↵ =5 %w e r en o t e da ss u c h .
3.4 Results and discussion
Our outcome (the di↵erence in Z-scores of weight-for-age for 6-months versus birth) was not
centred around 0 (mean/median of  0.29/   0.38 and  0.13/   0.18 for females and males
respectively), which raised concerns that our sample population was inappropriate for the
World Health Organization’s growth curves. We investigated the larger Norwegian Human
Milk Study cohort (n=3529), of which NOMIC is a subsample21.W ef o u n dt h a tt h em e d i a n
weight-for-age Z-score at birth was 0.76, decreasing to 0.31 at 6 months of life, inferring a
large proportion of macrosomic infants. However, if the Norwegian infants were naturally
born longer, then we would expect a naturally higher birth weight; we found the median
21M Eggesbo et al.: Levels of hexachlorobenzene (HCB) in breastmilk in relation to birth weight in a
Norwegian cohort, in: Environmental Research 109 (2009), pp. 559–66.44
Figure 3.3. Results from the time-speciﬁc analyses for males. Coloured areas indicate
signiﬁcant results at 20% FDR, and are labelled with their e↵ect estimates, while white
areas indicate non-signiﬁcant results. Signiﬁcant results at 5% FDR are indicated by ⇤.
Only the results for males are displayed, as no signiﬁcant results were found for females.45
weight-for-length Z-score at birth was 0.63, decreasing to 0.06 at 6 months. This suggests that
the Norwegian infants were born with more mass than one would expect for their appropriate
length. These ﬁndings from the larger Norwegian Human Milk Study cohort were similar to
what we found in NOMIC. Similar results have been shown in the Norwegian Medical Birth
Registry, where it has been found that from the early 1970s to the late 1990s the birthweight
of Norwegian infants has been increasing22. These ﬁndings strengthen the recommendations
from the Norwegian Health Directorate to use the World Health Organization’s growth
curves23.I ti sa l s ow o r t hn o t i n gt h a tb e c a u s et h ef e m a l ed i s t r i b u t i o ni sc e n t r e ds of a rf r o m
zero (mean/median of  0.29/ 0.38), we lack power when detecting gut microbiota patterns
that results in a positive change in Z-score.
We applied the above methods to each gut microbiota spp. group in Table 4.2 and
displayed signiﬁcant time-speciﬁc results in Figure 3.3 and pattern results in Figures 3.4 and
3.5.
In the time-speciﬁc analyses, with 5% FDR, we found the detection of Bacteroides spp.
(Probe 22) at day 30 to be signiﬁcantly associated with reducing growth in males, when
compared to non-detection (Figure 3.3). The current literature shows that Bacteroides spp.
is protective against obesity24.
In the pattern analyses, we note that the detection of Staphylococcus spp. (Probe 4) at
day 4 was associated with expected growth in females and males (Figures 3.4 and 3.5). The
literature highlights that colonisation of Staphylococcus spp. is a normal feature of healthy
gut ﬂora25.W ea l s of o u n dt h a tEscherichia coli (Probe 13) detection from day 4 through to 30
was associated with expected growth in males (Figure 3.5). The current literature indicates
22R Skjaerven/H Gjessing/L Bakketeig: Birthweight by gestational age in Norway, in: Acta Obstetricia et
Gynecologica Scandinavica 79 (2000), pp. 440–449.
23Arbeidsgruppe: Nasjonale faglige retningslinjer for veiing og maaling i helsestasjons - og skolehelsetjen-
esten (see n. 11).
24G Musson/R Gambino/M Cassader: Obesity, Diabetes, and Gut Microbiota, in: Diabetes Care 33 (2010),
pp. 2277–2284.
25P Mackowiak: The normal microbial ﬂora, in: The New England Journal of Medicine 307 (1982), pp. 83–
93.46
Figure 3.4. Results from the pattern analysis for females. The exposure pattern is
represented by four characters, constructed from “+”, “ ”, and “X”, which represent
detection, non-detection, and irrelevance, respectively, for the four time points of the
analysis (days 4, 10, 30, and 120). The blue points and lines represent estimated means
and 95% conﬁdence intervals for patterns that were found to be signiﬁcantly close to zero
at an FDR of 5%. The crude contrasts (i.e. if “+ XX” was signiﬁcant, the crude contrast
would be “ +XX”) that were signiﬁcantly di↵erent to zero at ↵ =5 %h a v et h e i re s t i m a t e d
means and 95% conﬁdence intervals displayed in red. For the testing of the di↵erence of
the means of the two patterns, signiﬁcant results (at ↵ =5 % )i si n d i c a t e db y⇤,o t h e r w i s e
signiﬁcance is ↵ =1 0 % .
that colonisation of Escherichia coli is a normal feature of healthy gut ﬂora development26.
We were concerned that our pattern analysis ﬁndings were caused by confounding that
occurred before four days of life. When comparing infants with detected Staphylococcus
spp. (Probe 4) at day 4 to those without, we found evidence that males with non-detected
Staphylococcus spp. (Probe 4) at day 4 had lower birthweight (mean 3.19 Kg vs 3.58 Kg)
and higher proportion of usage of the newborn intensive care unit, (25% vs 6%), however,
these ﬁndings were inverted in the female stratum (3.68 Kg vs 3.55 Kg and 0% vs 5%),
and we therefore found no conclusive evidence of confounding. We also found no noticeable
26HK Park et al.: Molecular analysis of colonized bacteria in a human newborn infant gut, in: The Journal
of Microbiology 43 (2005), pp. 345–353.47
Figure 3.5. Results from the non-parametric patterns analysis for males. The exposure
pattern is represented by four characters, constructed from “+”, “ ”, and “X”, which
represent detection, non-detection, and irrelevance, respectively, for the four time points of
the analysis (days 4, 10, 30, and 120). The blue points and lines represent estimated means
and 95% conﬁdence intervals for patterns that were found to be signiﬁcantly close to zero
at an FDR of 5%. The crude contrasts (i.e. if “+ XX” was signiﬁcant, the crude contrast
would be “ +XX”) that were signiﬁcantly di↵erent to zero at ↵ =5 %h a v et h e i re s t i m a t e d
means and 95% conﬁdence intervals displayed in red. For the testing of the di↵erence of
the means of the two patterns, signiﬁcant results (at ↵ =5 % )i si n d i c a t e db y⇤,o t h e r w i s e
signiﬁcance is ↵ =1 0 % .48
di↵erences in the rates of preeclampsia, poor fatal growth, gestational age, or maternal
BMI. No noticeable di↵erences were found in any of the above variables when checking for
confounding in Escherichia coli (Probe 13).
By investigating one overarching theme (“how does the gut microbiota a↵ect infant
growth?”) through two di↵erent questions, we obtained two di↵erent set of results. We
note that these two set of results are not mutually exclusive, nor contrasting in nature. In-
stead they o↵er di↵erent perspectives: the time-speciﬁc analysis aids in highlighting where
gut microbiota has an association with the mean of the outcome, which is useful in situations
where the outcome is shifted away from 0 and it is hard to ﬁnd a true “healthy reference
group”. The pattern analysis is useful in identifying how the gut microbiota develops over
time in babies with expected growth (i.e. we found that Escherichia coli (Probe 13) detec-
tion from day 4 through to 30 was associated with expected growth in males). This allowed
us to combine a number of exposures over time, which, when viewed together, formed a
cohesive message about the outcome. The message was that certain patterns corresponded
to expected growth, and deviation from those patterns was associated with not achieving
expected growth – instead of only identifying singular gut microbiota exposures that shifted
growth.
It is important to note that as no contrasts (beyond the crude contrasts) were compared
to the “expected growth” pattern, we cannot make inferences about the association between
expected growth and patterns that are partially di↵erent from the “expected growth” pat-
tern. We can only assert that the presence of particular exposure patterns are associated
with expected growth, and that they signiﬁcantly di↵ered from their crude contrasts (which
were also signiﬁcantly di↵erent from expected growth).
When considering the application of the pattern analysis method to other analyses, it is
important to note that it cannot account for confounding. We propose that in situations
where confounding variables are at work, the above method be used to extract a plausible
reference pattern, and then a traditional logistic regression strategy should be implemented49
to address confounding. This process of reference pattern selection adds value to the current
methodology literature, as it enables the transparent selection of a sensible reference pattern
in scenarios (such as the one above) where it is not a simple matter to select a baseline a
priori.
In certain situations, the outcome may be dependent on the interaction between two
gut microbiota spp. groups, which would result in the above method not being appropriate
without an extension. By creating patterns consisting of two – or more – gut microbiota
spp. groups, and then applying the methods described here, the intra-gut microbiota spp.
group dependencies can be accounted for.
As with all methods, we are limited by the granularity of our longitudinal observations
and the observational nature of our data. Our method identiﬁes time-dependent points
that may contain information about potential time-dependent exposure windows that are
reﬂected in the observed data. That is, if one assumes there is a time-dependent exposure
window requiring a microbe to be detected between 100-110 days, but the microbe does not
simply dissipate from the body at day 111, so a strong relationship exists between day 110
and 120, then the method will identify a time-dependent point at day 120 (reﬂecting the
time-dependent exposure window at days 100-110). This is simply a feature of the data, and
the length of time surrounding each time-dependent exposure window when it is reﬂected in
the data (i.e. when the microbes remain similar) may vary from microbe to microbe and be
dependent on the situation at hand.
The only way to prove that a time-dependent exposure window has occurred is through
experiments. Using observational data, our method provides a novel way to describe po-
tential time-dependent exposure windows that may have been reﬂected into the observable
data. These descriptions can be further used to create time-dependent hypotheses for ex-
periments concerned with the existence of time-dependent exposure windows. Furthermore,
we highlight that our statistical methods were designed to control the false discovery rate,
over a large number of tests. In doing so, it is likely that we discarded a number of clinically50
signiﬁcant ﬁndings that were not found to be statistically signiﬁcant. We therefore make no
claims about the gut microbiota spp. groups that were not found to have any signiﬁcant
results, as the absence of evidence is not evidence of absence.
3.5 Conclusion
Our results expand on the current literature relating gut microbiota to growth, in both
methodology and biological ﬁndings. With regards to methodology, we developed a novel
method to analyse longitudinal data that contains information about the development of
an ecosystem over time. Crucially, this method controls the false discovery rate associated
with multiple levels of multidimensional testing. We expanded the biological literature by
reporting time-dependent patterns associated with expected growth, which, in some cases,
conﬁrmed the importance of gut microbiota spp. groups previously reported on.Chapter 4
Using Bayesian distributed lag
two-part models to investigate the
e↵ect of persistent organic pollutants
(POPs) on gut microbiota in infants
4.1 Abstract
Gut microbiota has a critical role in human health; understanding its role in early infancy
is of particular interest due to the time dependent windows that rely on microbial stimulus
from the gut. That is, the development of tolerance and the optimal functioning of angiogen-
esis and stress responses later in life, require time dependent actions in the gut. Persistent
organic pollutants (POPs) are widespread environmental contaminants that are resistant to
environmental degradation through normal processes, which causes them to bioaccumulate
in human and animal tissue and biomagnify in food chains. POPs are known carcinogens
that disrupt natural human systems (endocrine, reproductive, and immune). Using novel
statistical models, we investigated the impact of POPs (in particular, non-dioxin-like poly-
5152
chlorinated biphenyl, IUPAC no.: 153; ”PCB153”) on human health through the disruption
of natural gut microbiota establishment in infants. We created novel distributed lag two-part
models to account for the cumulative exposure of POPs. We then identiﬁed signiﬁcant asso-
ciations concerning POPs a↵ecting gut microbiota species (spp.) groups (from birth through
to day 120 of life). Strong associations were found between POPs and Biﬁdobacterium spp.,
Biﬁdobacterium biﬁdum,a n dLactobacillus spp.. Using these ﬁndings we successfully identi-
ﬁed gut microbiota as a potential vector through which POPs may harm humans; examples
were given for POPs acting as carcinogens and diarrhoeal agents.
4.2 Introduction
Persistent organic pollutants (POPs) are widespread environmental contaminants that are
resistant to environmental degradation through normal processes; this causes them to bioac-
cumulate in human and animal tissue and biomagnify in food chains. Exposure to POPs can
cause death, as well as other illnesses related to the disruption of the endocrine, reproductive,
and immune systems1.F u r t h e r m o r e ,P O P sa r ek n o w nc a r c i n o g e n s 2.P O P sa r ec u r r e n t l yr e g -
ulated by the Stockholm convention (http://www.pops.int) and following the ban on them
as fungicides, environmental levels have declined by more than 90% worldwide. However,
POPs are still used as industrial chemicals and are created as an unintended by-product
from several processes, such as production of chlorinated solvents. Therefore, population
exposure to POPs is likely to continue, and as such, deserves attention.
Gut microbiota has a critical role in human health3; understanding its role in early
infancy is of special interest because the early life period is a determinant for the subsequent
adult-like microbiota. Once the ﬁrst microbes arrive in the sterile gut of the newborn, a
1L Ritter et al.: Persistent organic pollutantsgut, in: United Nations Environment Programme 2007.
2B Fisher: Most unwanted, in: Environmental Health Perspectives 107 (1999), A18–A23.
3Backhed et al.: Host-bacterial mutualism in the human intestine (see n. 1); Mitsuoka: Intestinal ﬂora and
aging (see n. 1); Roung/Mazmanian: The gut microbiota shapes intestinal immune responses during health
and disease. (See n. 1); Turnbaugh et al.: A core gut microbiome in obese and lean twins (see n. 1); Bjorksten
et al.: The intestinal microﬂora in allergic estonian and swedish 2-year-old children (see n. 1); Mazmaniam/
Round/Kasper: A microbial symbiosis factor prevents intestinal inﬂammatory disease. (See n. 1).53
dynamic process starts where activation of genes and expression of receptors in the host
plays an important role for the building of niches and the further selection of microbes.
More importantly, studies on germ free animals have revealed the presence of developmental
windows that rely on microbial stimulus from the gut4 (i.e. development of tolerance5), but
also for optimal functioning of diverse systems, such as angiogenesis6 and stress responses7.
However, we still have limited knowledge of early gut microbiota8.
We investigate the associations between POPs (in particular, non-dioxin-like polychlori-
nated biphenyl, IUPAC no.: 153; ”PCB153”) and disrupted natural gut microbiota estab-
lishment (from day 4 through to day 120), to identify a possible vector through which POPs
could a↵ect human health. Our high quality dataset includes a daily exposure proﬁle for
POPs in the infants, which allows our investigation to analyze the cumulative e↵ect of POPs
on gut microbiota. To achieve this, we developed a novel statistical method to overcome
the problem of estimating the cumulative e↵ect of POPs when large numbers of infants have
outcomes of zero - non-detected gut microbiota species (spp.) groups.
4Thompson/Wang/Holdes: The immediate environment during postnatal development has long-term im-
pact on gut community structure in pigs (see n. 2).
5Sudo et al.: The requirement of intestinal bacterial ﬂora for the development of an ige production system
fully susceptible to oral tolerance induction (see n. 3); Mazmanian et al.: An immunomodulatory molecule
of symbiotic bacteria directs maturation of the host immune system (see n. 3).
6Stappenbeck/Hooper/Gordon: Developmental regulation of intestinal angiogenesis by indigenous mi-
crobes via paneth cells (see n. 6).
7Sudo et al.: Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for
stress response in mice (see n. 7).
8M Wang et al.: T-rﬂp combined with principal component analysis and 16s rrna gene sequencing: an
e↵ective strategy for comparison of fecal microbiota in infants of di↵erent ages. In: Journal of Microbiological
Methods 59 (2004), pp. 53–69; C Palmer et al.: Development of the human infant intestinal microbiota. In:
PLoS Biology 5 (2007), pp. 1556–1573; C Favier et al.: Molecular monitoring of succession of bacterial com-
munities in human neonates, in: Applied and Environmental Microbiology 68 (2002), pp. 219–26; Eggesbo
et al.: Development of gut microbiota in infants not exposed to medical interventions (see n. 14).54
4.3 Methods
4.3.1 Study population
The Norwegian Microﬂora Study (NoMIC) is a birth cohort established to study the estab-
lishment of gut microbiota during infancy and its consequences for child health. Participating
mothers were recruited to the NoMIC study by a paediatrician at the maternity ward in a
county hospital in South Norway. Recruitment was designed to purposefully oversample
preterm children; whenever a preterm-birth mother was enrolled, two mothers of consecu-
tively born term infants were recruited. The recruitment started in November 2002 and was
completed in May 2005. Eligibility criteria for the study were that mothers must be ﬂuent
in Norwegian and resident in the pertinent geographic area. The study was approved by the
Norwegian Data Inspectorate and the Regional Ethics Committee for Medical Research.
After the informed consent form had been signed by the mothers, containers for fecal
samples and a questionnaire were provided to the participants at the maternity ward. The
mothers were asked to collect and freeze one fecal sample from themselves at postpartum
day 4, as well as samples from their infants when they were 4, 10, 30, and day 120 old. Study
personnel retrieved the fecal samples and kept them frozen during transport to the Biobank
of the Norwegian Institute of Public Health, where they were stored at -20 C upon arrival.
Further questionnaires were sent to the families when their infants were aged 6, 12, 18, and
24 months.
Six hundred and one mothers agreed to participate in the NoMIC study, however, 86
(14%) of these mothers never returned any fecal samples, which left 524 infants with available
fecal samples from one or more occasions. There were no checks performed on demographic
data to identify if the data is not missing completely at random.
All the mothers were directed to save a 25ml milk sample from each morning for eight
consecutive days, although milk sampled in a di↵erent manner was also accepted. The
pooled milk samples were collected by study personnel and kept frozen during transport.55
Table 4.1. Description of participants
Subsample Full NoMIC cohort
Sample size 73 524
Male 55.0 54.1
Maternal smokers 11.2 15.2
Siblings 0( 0 ,1 ) 1( 0 ,1 )
Birth weight (Kg) 3.3 (2.7, 3.7) 3.4 (2.6, 3.8)
Maternal age 29 (27, 32) 30 (27, 33)
Maternal BMI 23.6 (21.7, 26.2) 23.9 (21.2, 27.2)
List of characteristics in the whole NoMIC study and those selected to have milk analysis.
Results are presented as either % or median (interquartile range). Sample size is presented
as number in selection.
The median age at start of sampling was 33 days after delivery (min 2 days, max 124; 5th
percentile 16 and 95th percentile 65).
For reasons of cost, we randomly selected 73 infants from among the term children in
the NoMIC cohort, and in whom milk samples had been collected, for toxicant analysis.
Concentrations of non-dioxin-like polychlorinated biphenyl (ndl-PCBs; IUPAC no.: 153,
”PCB153”) were then measured in approximately 15 ml of breast milk at the Norwegian
School of Veterinary Science in Oslo. Characteristics of the NoMIC cohort and the subsample
are presented in Table 4.1.
4.3.2 Outcomes
The outcomes of interest were intensity readings for 22 probes, encoding for di↵erent gut
microbiota spp. groups at 4, 10, 30, and 120 days since birth. The gut microbiota spp.
groups, labelling sequence, and target bacteria (according to TNTProbeTool program) are
displayed in Table 4.2.
16S rRNA gene clone libraries were constructed from DNA extracted from the fecal
samples obtained on days 4, 10, 30, and 120. More detailed information about this process56
can be found in a previous paper9.
These intensity levels were analysed as a continuous variable (Yi), which was rescaled to
fall between 0 and 100, for the subset of 73 infants. Each gut microbiota spp. group was
analyzed separately.
4.3.3 Exposures
The exposures of interest were the blood lipid POPs levels (PCB153) in the infants. To esti-
mate these levels across the ﬁrst day 120 of life, we used a previously developed and validated
toxicokinetic model11. Brieﬂy, this toxicokinetic model has two compartments representing
maternal and child lipids that are connected through placental di↵usion and excretion/intake
of breast milk. The mother is exposed to POPs through ingestion of contaminated food
whereas the child is exposed both through placental di↵usion and consumption of breast-
milk. Elimination of POPs from the maternal and child compartments was parameterised
based on published half-life values.
We generated proﬁles of blood lipid POPs levels, for each child, by including information
on age at delivery, pre-pregnancy weight, weight gain during pregnancy and loss thereafter,
gestational age, sex, child weight at birth and onwards, duration of breast-feeding and the
percentage of total intake attributable to breast-feeding when other food is incorporated
into child’s diet. Oral intake in mothers was optimised to match simulated breast milk levels
to those measured in the study. Subsequently, every child POPs levels were estimated (for
every 24 hours of life) to be used as estimates of their exposure to POPs.
To aid in interpretation of the results, the concentrations of the POPs were rescaled such
that 1 unit corresponded to the di↵erence between the 25th and 75th percentiles (of the
subset of 73 infants) on day 0 of life.
9Eggesbo et al.: Development of gut microbiota in infants not exposed to medical interventions (see n. 14).
11M Verner: Submitted, in: 2012.57
Table 4.2. Probes and their targets
# Probe match Labelling probes
1 Enterococcus spp. TCATCCCTTGACGGTATCTAA
2 Lactobacillus spp. GTCAAATAAAGGCCAGTTACTA
3 Lactobacillus paraca-
sei/casei
CAGTTACTCTGCCGACCATT
4 Staphylococcus spp. ACACATATGTTCTTCCCTAATAA
5 Streptococcus spp. (↵-
hemolytic)
AGTGTGAGAGTGGAAAGTTCA
6 Clostridium spp. TCAACTTGGGTGCTGCATTC
7 Lachnospiraceae spp. AGCTAGAGTGTCGGAGAGG
8 Veillonella spp. GATTGGCAGTTTCCATCCCAT
9 Lachnospiraceae spp. TATCAGCAGGAAGATAGTGA
10 Lachnospiraceae spp. AGTCAGGTACCGTCATTTTCT
11 Lachnospiraceae spp. ACTGCTTTGGAAACTGCAGAT
12 Pseudomonas spp. GTAGAGGGTGGTGGAATTTC
13 Escherichia coli GAGCAAAGGTATTAACTTTACTC
14 Enterobacteriaceae other
than E. coli
CGAAACTGGCAGGCTAGAGT
15 Gammaproteobacteria CCTGGACAAAGACTGACGCT
16 Varibaculum spp. TTGAGTGTAGGGGTTGATTAG
17 Biﬁdobacterium longum
including subsp infantis
GAGCAAGCGTGAGTAAGTTTA
18 Biﬁdobacterium biﬁdum CCGAAGGCTTGCTCCCAAA
19 Biﬁdobacterium breve CACTCAACACAAAGTGCCTTG
20 Biﬁdobacterium spp. GCTTATTCGAAAGGTACACTCACCCCGAAGGG
21 Bacteroides fragilis GGGCGCTAGCCTAACCAG
22 Bacteroides spp. ATGCATACCCGTTTGCATGTA
Targets of the probes found using TNTProbeTool program, taken from previous paper10.58
4.3.4 Confounders
Information on potential confounders were obtained by questionnaires ﬁlled in by the mothers
and the Medical Birth Registry of Norway.
It was decided a priori that potential confounders were breastfeeding, education, gender,
gestational age, maternal age, parity, and smoking. All confounders were then added to
the models and stepwise reduction procedures were used to identify confounders (those that
a↵ected the 95th percentile e↵ect estimates of POPs by more than 10% in the gut microbiota
spp. groups that had a possible association). These were found to be all of the variables
tested, and were denoted as ~ Q.
Breastfeeding was analysed as a continuous variable at days 4, 10, and 30. The variable
had four levels, corresponding to the child never having any milk substitutes, once or twice
having milk substitutes, once or twice a week having milk substitutes, and only having milk
substitutes. Breastfeeding was also analysed as the proportion of meals that were breast milk
in the fourth month of life (corresponding to the time period close to day 120). Education
was analysed as a continuous variable, with four levels corresponding to less than high school,
high school, completed some of a university degree, and having completed a university degree.
Gestational age was calculated based on the last menstrual period. In Norway ultrasound is
routinely performed in the second trimester, and we used the ultrasound-based estimate only
if the discrepancy between the two exceeded 14 days12.P a r i t yw a sa n a l y s e da sac o n t i n u o u s
variable containing the number of siblings. Maternal smoking status at the beginning of
pregnancy was dichotomised into never/previously and occasional/daily.
12T Henrisken et al.: Bias in studies of preterm and postterm delivery due to ultrasound assessment of
gestational age. In: Epidemiology 6 (2005), pp. 533–537; B Blondel et al.: Algorithms for combining menstrual
and ultrasound estimates of gestational age: consequences for rates of preterm and postterm birth. In: BJOG:
An International Journal of Obstetrics and Gynaecology 109 (2002), pp. 718–720.59
4.3.5 Models
Our models were designed to analyze the cumulative e↵ect of POPs on the 22 gut microbiota
spp. groups. To avoid any issues caused by infant gut microbiota’s ill-deﬁned and non-
parametric relationship with time, cross sectional analyses were performed with the outcome
at days 4, 10, 30, and 120. Due to the large number of non-detections (Yi =0 ) ,t h ed a t aw e r e
primarily analysed using two-part models13.T h ef o l l o w i n gm o d e l sw e r ea p p l i e di n d i v i d u a l l y
to each of the 22 gut microbiota spp. groups.
For the model with the outcome at day 120, distributed lag two-part models were im-
plemented to estimate the cumulative e↵ect of POPs on the intensity readings of probes
corresponding to gut microbiota spp. groups14:
E[Y(120)i|~ Q(t120i, ~ X(120)i]=P(Y(120)i   0|~ Q(120)i, ~ X(120)i) ⇥ E[Y(120)i|Y(120)i   0, ~ Q(120)i, ~ X(120)i]
(4.1)
where infants i =1 ,...,73, ~ Q(120)i were the confounders, ~ X(120)i was a vector containing
blood concentrations of POPs at days 0,10,20,...,and 120.
P(Y(120)i   0|~ Q(120)i, ~ X(120)i)w a se s t i m a t e du s i n gad i s t r i b u t e dl a gp r o b i tr e g r e s s i o n :
P(Y(120)i   0|~ Q(120)i, ~ X(120)i)= 
⇣
 0 + ~  1
0~ Q(120)i +  2X(0)i +  3X(10)i +  4X(20)i + ···+  14X(120)i
⌘
and E[Y(120)i|Y(120)i   0, ~ Q(120)i, ~ X(120)i] was estimated using a distributed lag linear regression
restricted to the detectable (non-zero) data:
E[Y(120)i|Y(120)i   0, ~ Q(120)i, ~ X(120)i]= 0+~  1
0~ Q(120)i+ 2X(0)i+ 3X(10)i+ 4X(20)i+···+ 14X(120)i
Further detailed information about the construction of two-part models and distributed lag
13N Duan et al.: A Comparison of Alternative Models for the Demand for Medical Care. Santa Monica
1982.
14L Welty et al.: Bayesian distributed lag models: Estimating e↵ects of particulate matter air pollution on
daily mortality. In: Biometrics 65 (2009), pp. 282–291.60
models can be found in the appendix.
For the models with outcomes at days 4, 10, and 30, distributed lag models were not
needed as there were negligible di↵erences in blood concentration from day 0 through to 30.
Hence only the concentrations of POPs at the day of the outcome were used as the measure
of exposure (i.e cumulative exposure contained the same information as acute exposure):
E[Y(t)i|~ Q(t)i,X (t)i]=P(Y(t)i   0|~ Q(t)i,X (t)i) ⇥ E[Y(t)i|Y(t)i   0, ~ Q(t)i,X (t)i]
where infants i =1 ,...,73, ~ Q(t)i were the confounders, X(t)i were the blood concentrations
of POPs at time (t), and (t)i d e n t i ﬁ e sw h i c ho ft h et h r e ec r o s ss e c t i o n a lm o d e l si sb e i n g
referred to (t =4 ,10,30). P(Y(t)i   0|~ Q(t)i,X (t)i)w a sc a l c u l a t e du s i n gap r o b i tr e g r e s s i o n ,
while E[Y(t)i|Y(t)i   0, ~ Q(t)i, ~ X(t)i] was calculated using a linear regression restricted to the
detectable (non-zero) data.
When there were less than ﬁve non-detections, the data were analysed using linear re-
gression models. Further detailed information regarding the construction of these models is
available in the appendix.
4.4 Results and discussion
Our time-speciﬁc ﬁndings for spp. groups, which have at least one signiﬁcant result, are
displayed in Table 4.3. From Table 4.3 we can see that Biﬁdobacterium spp. (Probe 20),
Biﬁdobacterium biﬁdum (Probe 18), and Lactobacillus spp. (Probe 2) have strong, clearly
deﬁned associations with POPs.
Biﬁdobacterium spp. (Probe 18) had a signiﬁcant negative association with POPs at all
four time points, which was increasing in strength over time (Table 4.3). Some Biﬁdobac-
terium strains have been shown to produce folate in the colon15 in addition to transport
15A Pompei/et al: Folate production by biﬁdobacteria as a potential probiotic property. In: Applied and
Environmental Microbiology 73 (2007), pp. 179–185.61
Table 4.3. Signiﬁcant associations
# Probe match Day 4 Day 10 Day 30 Day 120
1 Enterococcus spp.  7.6
( 13.4,4.4)
 11.4⇤
( 16.4, 3.1)
 2.3
( 6.9,5.7)
 14.6⇤
( 29.3, 2.8)
2 Lactobacillus spp.  5.8⇤
( 12.1, 0.3)
 4.7
( 12.4,3.8)
1.4
( 5.0,13.1)
1.8
( 4.1,11.9)
18 Biﬁdobacterium bi-
ﬁdum
 9.5⇤
( 16.4, 2.9)
 9.9⇤
( 17.1, 2.5)
 9.0⇤
( 13.8, 2.9)
 13.7⇤
( 28.4, 2.3)
20 Biﬁdobacterium spp.  11.5⇤
( 17.7, 3.5)
 6.2⇤
( 11.8, 0.3)
 6.2
( 11.0,0.0)
 3.6
( 10.3,4.0)
3 Lactobacillus paraca-
sei/casei
 3.1
( 15.3,3.5)
 6.6⇤
( 14.1, 1.5)
 1.7
( 6.6,6.7)
 5.6
( 17.7,4.8)
4 Staphylococcus spp.  3.1
( 11.6,5.6)
1.9
( 5.1,9.0)
 2.2
(( 12.6,4.4))
 5.8⇤
( 10.2, 1.3)
Probes with at least one signiﬁcant association found. Signiﬁcance at ↵ =5 %i sd e n o t e db y
⇤
anticancer genes into tumours16.W en o t et h a tP O P sh a v eb e e ns h o w nt op l a yar o l ei n
cancer causation17.
In contrast to the previous sustained association, Biﬁdobacterium biﬁdum (Probe 18) only
had a signiﬁcant negative association with POPs at days 4 and 10 (borderline signiﬁcant at
day 30), with the association decreasing in magnitude over time (Table 4.3). Biﬁdobacterium
biﬁdum has been shown to be protective against diarrhoeal diseases18 and allergies19,w h i l e
POPs are known to negatively impact immune systems20.
Finally, we found that Lactobacillus spp. (Probe 2) had a similar signiﬁcant negative
association with POPs at day 4, decreasing to a slightly smaller in magnitude (and non-
signiﬁcant) association at day 10 (Table 4.3). As with Biﬁdobacterium,s o m eLactobacillus
16X Li/et al: Biﬁdobacterium adolescentis as a delivery system of endostatin for cancer gene therapy:
Selective inhibitor of angiogenesis and hypoxic tumor growth. In: Cancer Gene Therapy 10 (2003), pp. 105–
111.
17Fisher: Most unwanted (see n. 2).
18J Saavedra et al.: Feeding of biﬁdobacterium biﬁdum and streptococcus thermophilus of inants in hospital
for prevention of diarrhoea and shedding of rotavirus. In: The Lancet 344 (1994), pp. 1046–1049.
19J Kim et al.: E↵ect of probiotic mix (biﬁdobacterium biﬁdum, biﬁdobacterium lactis, lactobacillus aci-
dophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. In: 21
(2010), pp. 386–393.
20Ritter et al.: Persistent organic pollutantsgut (see n. 1).62
strains have been shown to act as anticancer agents21,a n da g a i nn o t i n gt h a tP O P sh a v e
been shown to play a role in cancer causation22.
We developed and implemented a distributed lag probit regression model. This model
was then used to create a distributed lag two-part model, which was ultimately used to
account for the large number of non-detected gut microbiota intensity readings. This novel
distributed lag two-part model was applied to gut microbe data; while distributed lag models
are common in environmental epidemiology, as far as we know, this is the ﬁrst time such a
method has been used in microbe data.
To the best of our knowledge, this is the ﬁrst study to examine POPs a↵ecting gut
microbiota. Through the identiﬁcation of such associations, we can better understand the
kinetics of disease associated with POPs. Such pathways have been tentatively identiﬁed for
cancer and diarrhoeal diseases caused by POPs.
21S Choi et al.: E↵ects of lactobacillus strains on cancer cell proliferation and oxidative stress in vitro, in:
42 (2006), pp. 452–458.
22Fisher: Most unwanted (see n. 2).Appendix A
Novel developmental analyses identify
longitudinal patterns of early gut
microbiota that a↵ect infant growth
For k =1 ,...,22 gut microbiota spp. groups with j =1 ,...,16 patterns, let the p-values
of the patterns jk,4, jk,4 without day 120 (jk,3), jk,4 without days 30 and 120 (jk,2), and jk,4
without days 10, 30, and 120 (jk,1), be denoted as Pjk,4, Pjk,3, Pjk,2,a n dPjk,1,r e s p e c t i v e l y .
These patterns are considered to be part of the pattern family jk.W e a i m t o t e s t t h e
following:
H0 :m i n
 
|µjk,4|,|µjk,3|,|µjk,2|,|µjk,1|
 
  0.67
H1 :m i n
 
|µjk,4|,|µjk,3|,|µjk,2|,|µjk,1|
 
< 0.67
Given an arbitrary signiﬁcance level ↵⇤, the following procedures are performed after ﬁnding
af o u rt i m ep o i n tp a t t e r njk,4 whose mean is signiﬁcantly close to zero:
1. If Pjk,4 <↵ ⇤/2, then jk,3 is tested at signiﬁcance level ↵⇤/2
2. If Pjk,3 <↵ ⇤/3, then jk,2 is tested at signiﬁcance level ↵⇤/3
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3. If Pjk,2 <↵ ⇤/4, then jk,1 is tested at signiﬁcance level ↵⇤/4
The Bonferroni adjusted p-value for gut microbiota spp. group k is denoted as
Pk = (num patterns tested in gut microbiota spp. group k) ⇥ minj2k(Pjk,4)
Without loss of generality, we will prove that the FDR is controlled when step 1 is imple-
mented - proofs for the other steps are similarly formed. This proof relies on the proof pro-
vided in Guo et al. (2010). We let V be the number of false positives, I1 = {1  k  22|H1}
be the set of indices of false null hypotheses, ↵⇤ = ↵ ⇥ R/(22 ⇥ 16) (obtained from Guo et
al., 2010), and I(·) be an indicator function. We then express V as:
V =
X
k2I1
I
 
[
16
j=1 (Reject H0 for jk|H0)
 
=
X
k2I1
I
 
[
16
j=1
  
↵
⇤/2  Pjk,4  ↵
⇤|H0
 
+
 
Pjk,4  ↵
⇤/2,P jk,3  ↵
⇤/2|H0
   
Then
FDR=E
⇢
V
R _ 1
 
=E
⇢
E(V |R = r)
R _ 1
 
=E
"P
j2I1 Pr
 
[16
j=1
  
↵⇤/2  Pjk,4  ↵⇤|H0
 
+
 
Pjk,4  ↵⇤/2,P jk,3  ↵⇤/2|H0
  
|R = r
 
R _ 1
#
=
22 X
r=1
X
k2I1
1
r
Pr
 
[
16
j=1
  
↵
⇤/2  Pjk,4  ↵
⇤,R= r|H0
 
+
 
Pjk,4  ↵
⇤/2,P jk,3  ↵
⇤/2,R= r|H0
   

22 X
r=1
X
k2I1
16 X
j=1
1
r
 
Pr
 
↵
⇤/2  Pjk,4  ↵
⇤,R= r|H0
 
+P r
 
Pjk,4  ↵
⇤/2,P jk,3  ↵
⇤/2,R= r|H0
  
The above inequality follows from the Bonferroni inequality.
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
22 X
r=1
X
k2I1
16 X
j=1
1
r
 
Pr
 
↵
⇤/2  Pjk,4  ↵
⇤,R= r|H0
 
+
max
 
Pr
 
Pjk,4  ↵
⇤/2,R= r|H0
 
,Pr
 
Pjk,3  ↵
⇤/2,R= r|H0
   
=
22 X
r=1
X
k2I1
16 X
j=1
1
r
 
Pr
 
↵
⇤/2  Pjk,4  ↵
⇤|H0
 
⇥ Pr
 
R
( k) = r   1
 
+
max
 
Pr
 
Pjk,4  ↵
⇤/2|H0
 
,Pr
 
Pjk,3  ↵
⇤/2|H0
  
⇥ Pr
 
R
( k) = r   1
  
The above simpliﬁcation results from the assumption that each gut microbiota spp. group
is independent of each other, where R
( k) denotes the number of rejections in the step up
procedure with critical constants al =
l +1
22
,l=1 ,...,22   1b a s e do n{P1,...,P 22}\{Pk}

22 X
r=1
X
k2I1
16 X
j=1
1
r
 
↵
⇤/2 ⇥ Pr
 
R
( k) = r   1
 
+ max(↵
⇤/2,↵
⇤/2) ⇥ Pr
 
R
( k) = r   1
  
The above inequality follows from Pr(pvalue  p)  p, for any p 2 (0,1) under H0
=
22 X
r=1
X
k2I1
16 X
j=1
1
r
 
↵
⇤ ⇥ Pr
 
R
( k) = r   1
  
=
22 X
r=1
X
k2I1
16 X
j=1
1
r
 
↵ ⇥ R/(22 ⇥ 16) ⇥ Pr
 
R
( k) = r   1
  
=
m1
22
↵
=
m1
m
↵
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Table A.1. Probes and the frequency of their detection
# Female
Day 4
Female
Day
10
Female
Day
30
Female
Day
120
Male
Day 4
Male
Day
10
Male
Day
30
Male
Day
120
1 56 51 54 66 64 51 54 62
2 40 47 50 36 25 37 44 34
3 49 59 60 61 62 55 61 72
4 91 98 84 60 96 94 83 58
5 46 54 48 25 49 45 54 36
6 42 42 43 55 40 40 48 69
7 27 26 34 51 29 28 26 54
8 30 52 68 67 28 48 71 66
9 48 49 53 67 44 48 56 70
10 48 49 59 75 53 60 62 72
11 63 57 65 61 60 64 59 68
12 68 71 70 57 71 72 66 64
13 62 63 60 80 63 67 66 72
14 75 81 81 88 86 89 82 89
15 86 91 94 98 92 95 91 94
16 37 29 36 39 31 31 27 51
17 84 81 80 84 84 84 83 87
18 82 79 83 88 73 81 83 86
19 50 55 59 63 39 48 54 66
20 79 80 84 83 74 76 77 79
21 35 30 35 31 29 27 30 19
22 68 47 63 61 52 47 48 45
The frequency of the detection of each probe, stratiﬁed by sex and day. Information is
presented as percent detected.Appendix B
Using Bayesian distributed lag
two-part models to investigate the
e↵ect of persistent organic pollutants
(POPs) on gut microbiota in infants
B.1 Two-part models
The two-part model expressed in Equation 4.1 is comprised of two independent parts:
P(Y(t)i   0) and E[Y(t)i|Y(t)i   0, ~ Q(t)i, ~ X(t)i]1.
To estimate P(Y(t)i   0), the intensity levels were dichotomised into detected (Z(t)i =1 )
and non-detected (Z(t)i =0 ) .W em o d e lZ(t)i using probit regressions by introducing a latent
unobserved variable Z⇤
(t)i
2:
Z(t)i =
8
> <
> :
1i f Z⇤
(t)i   0
0i f Z⇤
(t)i < 0
1Duan et al.: A Comparison of Alternative Models for the Demand for Medical Care. (See n. 13).
2J Albert/S Chibl: Bayesian analysis of binary and polychromous response data. In: 88 (1993), pp. 669–
679.
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Where Z⇤
(t)i ⇠ N
⇣
E[Z⇤
(t)i],1
⌘
.T h i sc a nt h e nb ei n t e r p r e t e da san o r m a lr e g r e s s i o np r o b l e m
where the response is in the form of grouped data3. We deﬁne the conditional expectation
of Z⇤
(t)i as:
E
⇣
Z
⇤
(t)i|~ Q(t)i, ~ X(t)i
⌘
= ~  
⇤
(t)~ Q(t)i + ~ ✓
⇤
(t) ~ X(t)i
where people i =1 ,...,n, ~ Q(t)i were the confounders, ~ X(t)i were the blood concentrations of
POPs, and separate analyses were performed for days t =4 ,10,30, and 120.
The fully conditional posterior distributions of Z⇤
(t)1,...,Z⇤
(t)N are independent with4:
Z
⇤
(t)i|~ Qi, ~ Xi,Z (t)i ⇠
8
> <
> :
N(E[Z⇤
(t)i|~ Qi, ~ Xi],1) truncated at the left by 0 if Z(t)i =1
N(E[Z⇤
(t)i|~ Qi, ~ Xi],1) truncated at the right by 0 if Z(t)i =0
(B.1)
To estimate E[Y(t)i|Y(t)i   0, ~ Q(t)i, ~ X(t)i], we model Y(t)i using linear regressions on the
non-zero subset of the data:
Y(t)i|Y(t)i   0,Q (t)i,X P(t)i = ~  (t)~ Q(t)i + ~ ✓(t) ~ X(t)i + ✏(t)i
where people i =1 ,...,n, ~ Q(t)i were the confounders, ~ X(t)i were the blood concentrations of
POPs, and separate analyses were performed for days t =4 ,10,30, and 120.
As there were negligible di↵erences in blood concentration from day 0 to 30, concen-
trations at the day of response were used as the measure of exposure to chemicals. This
was not appropriate when considering an outcome at day 120, as the blood concentrations
varied a non-nominal amount between day 0 and 120. To capture and account for these
di↵erences over time, a vector containing blood concentrations at days 0,10,20,...,110, and
120 was used as the exposure. The models with an outcome at day 120 used distributed lag
models to account for the inherent problems with ﬁtting models containing highly correlated
covariates.
3Albert/Chibl: Bayesian analysis of binary and polychromous response data. (See n. 2).
4Ibid.69
Once estimated distributions were obtained for ~  ⇤
(t), ~ ✓⇤
(t), ~  (t) and ~ ✓(t),w es i m u l a t e d1 0 , 0 0 0
possible realisations of the coe cient vectors. These vectors were multiplied against ~ Q(t)i,
~ X(t)i,a n d ~ X⇤
(t)i +~ 1t oe s t i m a t eE[Y(t)i|~ Q(t)i, ~ X(t)i]a n dE[Y(t)i|~ Q(t)i, ~ X(t)i +~ 1].
The overall estimate of the e↵ect from a 1 unit change of POPs was calculated by:
 (t)i = E[Y(t)i|~ Q(t)i, ~ X(t)i +~ 1]   E[Y(t)i|~ Q(t)i, ~ X(t)i]
¯  (t) =
P
i  (t)i/n was calculated for each of the 10,000 possible realisations of the coe cient
vectors. The resultant empirical distributions of ¯  (t) were then used to calculate median
estimates and conﬁdence intervals for each of the ﬁtted models.
B.2 Distributed lag models from Welty et al (2009)
Distributed lag models are regression models that include lagged exposure variables (or
distributed lags) as covariates5.W ei m p l e m e n t e dt h e mt oe s t i m a t et h es h o r t - t e r mc u m u l a t i v e
e↵ect of chemical toxicants in infants on gut microbiota spp. groups.
We have outcome variables Y(t)1,...,Y (t)N (N people at time t). We aim to model these
outcomes using exposure time series X(t)i. We consider the general normal linear model:
E[Y(t)i|X(1)i,...,X (t)i]=
L X
l=0
✓lX(t l)i (B.2)
with Y(t)i ⇠ N(E[Y(t)i], 2).
The main di culty in distributed lag models is specifying a prior on ~ ✓ =( ✓0,✓ 1,...✓ L)T
that is uninformative on the distributed lag coe cients for small l (i.e. close to the time
of the outcome) but that constrain the coe cients with larger l (further in the past) to be
smoother and approach zero.
It is assumed that ~ ✓ ⇠ N(0,⌦), where ⌦ is constructed so that for increasing lag the
5Welty et al.: Bayesian distributed lag models: Estimating e↵ects of particulate matter air pollution on
daily mortality. (See n. 14).70
diagonal elements decrease to zero (Var(✓l) ! 0) and the o↵-diagonal elements in its correla-
tion matrix increase to one (Cor(✓l 1,✓ l) ! 1). One approach is to deﬁne ⌦ = ABA,w h e r e
AA
T is the diagonal matrix of the individual variances of the ✓lsa n dB is the correlation
matrix for ~ ✓.I ti sp o s s i b l et oa c h i e v ea na p p r o p r i a t e⌦ by setting A equal to the Cholesky
decomposition of a diagonal matrix with the desired prior variances and setting B equal to
the correlation matrix for increasingly correlated normal random variables.
We deﬁne:
V (⌘j)=
2
6 6 6 6
6 6 6 6 6 6
4
10 0. . . 0
0e x p ( ⌘j ⇥ 1)1/2 0. . . 0
00e x p ( ⌘j ⇥ 2)1/2 ... 0
. . .
. . .
. . .
. . .
00 0. . . e x p ( ⌘j ⇥ L)1/2
3
7 7 7 7
7 7 7 7 7 7
5
Q = V (⌘2)~ F1 + {IL+1   V (⌘2)}~ 1L+1F2, where
~ F1 ⇠ N(0,IL+1)
F2 ⇠ N(0,1), which gives
M(⌘2)=c o v ( Q)
= V (⌘2)V (⌘2)
T + {IL+1   V (⌘2)}~ 1L+1 ⇥~ 1
T
L+1{IL+1   V (⌘2)}
T
We then additionally deﬁne  2 as the prior variance of ✓0 and the hyper parameter ⌘1 (⌘1  0)
determines how quickly the prior variances of the ✓lst e n dt o w a r d sz e r o .~ 1L+1 is a (L+1)⇥1
vector of ones and IL+1 is the (L+1)⇥(L+1)identitymatrix. W ethendeﬁneA =  V (⌘1)
and B = W(⌘2); the latter of which is equal to the correlation matrix derived from the
covariance matrix M(⌘2).
B = W(⌘2)i st h ec o r r e l a t i o nm a t r i xf o rt h em i x t u r eo fn o r m a lr a n d o mv a r i a b l e sQ.T h e
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ﬁrst few elements of the dependent ~ 1L+1F2,a n dt h el a t t e re l e m e n t so ft h ed e p e n d e n t~ 1L+1F2
are weighted more heavily than the latter elements of the independent ~ F1.T h ep a r a m e t e r
⌘2 controls how quickly the mixture moves from independent to dependent. Hence the prior
prior on ~   is N(0, 2⌦(~⌘ )), where ⌦(~⌘ )=V (⌘1)W(⌘2)V (⌘1)a n d~⌘ =( ⌘1,⌘ 2)T.
We deﬁne ˆ ~   and ˆ ⌃ as the maximum likelihood estimates of the unconstrained distributed
lag coe cients and sample covariance matrix (from Equation B.2), resulting in the posterior
for ~   conditional on ~⌘ and  :
~  |ˆ ~  ,~ ⌘, 
2 ⇠ N
⇣
{1/ 
2⌦(⌘)
 1 + ˆ ⌃
 1
}
 1 ˆ ⌃
 1ˆ ~  ,{1/ 
2⌦(~⌘ )
 1 + ˆ ⌃
 1
}
 1
⌘
(B.3)
The hyperparameter  2 is assumed to be ten times the estimated statistical variance
of ✓0; di↵use enough to have little inﬂuence on the ﬁrst few ✓ coe cients. After setting a
discrete uniform prior of ~ N1 ⇥ ~ N2 on ~⌘ it is possible to obtain the posterior in a closed form
for a given ~⌘ ⇤:
p(~⌘
⇤|ˆ ~ ✓)=
| 2⌦(~⌘ ⇤)ˆ ⌃
 1
+ I| 1/2exp

 1
2
⇢
ˆ ⌃
 1
  ˆ ⌃
 1 ⇣
ˆ ⌃
 1
+ 1
 2⌦(~⌘ ⇤) 1
⌘ 1
ˆ ⌃
 1
 
ˆ ~ ✓
 
P
⌘2 ~ N1⇥ ~ N2 | 2⌦(~⌘ )ˆ ⌃
 1
+ I| 1/2exp

 1
2
⇢
ˆ ⌃
 1
  ˆ ⌃
 1 ⇣
ˆ ⌃
 1
+ 1
 2⌦(~⌘ ) 1
⌘ 1
ˆ ⌃
 1
 
ˆ ~ ✓
 
(B.4)
With su ciently large ranges for ~ N1 and ~ N2,t h ed a t ad r i v e st h es t r e n g t h( o rw e a k n e s s )o f
the prior distribution, which thus controls the eventual smoothness of the estimated function
-e s t i m a t e df r o mt h ed a t a .
B.3 Final Gibbs sampler implementation
We can use the equations6 from Welty et al (2009), which are listed in the previous section,
to constrain our estimates and hence adjust for the high levels of collinearity. For linear
6Welty et al.: Bayesian distributed lag models: Estimating e↵ects of particulate matter air pollution on
daily mortality. (See n. 14).72
regressions, a standard regression is ﬁt to obtain ~ ✓P, ~ ✓H, ~ ✓D and their respective covariance
matrices. For each of the ~ ✓ and ⌃, we apply Equations B.3 and B.4 in a Gibbs sampler,
which constrains the parameters in the aforementioned manner. For probit models, a Gibbs
sampler must be used to alternate between Equations B.1, B.3, and B.4.
To include multiple lagged variables or other variables (confounders), we make a simple
alteration to the prior covariance matrix. We being by deﬁning ⌃0j = ⌦(~⌘ ⇤)w h e r ej =
1,...,J is the index of lagged variables. We then deﬁne the prior covariance matrix as:
⌃0 =
2
6 6
6 6 6 6 6
6 6 6
4
⌃01 0 ... 00
0⌃ 02 ... 00
. . .
. . .
. . .
. . .
0 ... ... ⌃0J 0
0 ... ... 0   ⇥ I
3
7
7 7 7 7 7 7
7 7 7
5
where I is an identity matrix and   is a su ciently large number to produce a non-
informative variance prior on the confounders in the model, which are positioned in the
bottom right quadrant of the design matrix. ⌃0 can then be used to replace ⌦(~⌘ ⇤)i nE q u a -
tion B.3. In doing so, we have created distributed lag models that allow multiple lagged
variables, as well as other coe cients, which are implemented in both linear and probit
regressions.